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ABSTRACT
Multiple sclerosis (MS) is a leading cause of neurological disability in
young adults. Although current treatments can reduce symptomology and
relapse rate, they are unable to prevent the chronic neurodegeneration that
occurs at later stages. MS pathology is mediated by complex interactions
between invading immune cells, neurons, glia, and endogenous stores of neural
progenitor cells (NPCs). Factors critical to NPC/immune cell communication as
well as the survival, differentiation, and proliferation of NPCs are not well defined.
Elucidation of these factors will allow for the advancement of NPC transplantation
therapies as well as the identification of novel pharmacological targets.
Fas – a member of the tumor necrosis superfamily of death receptors –
has diverse, cell-specific functions and is a major modulator of autoregulation
within the immune system. Although Fas is expressed by NPCs, its exact role in
this cell type was previously unknown. To contribute to this body of knowledge,
the experiments in this dissertation examined the role of the Fas receptor (Fas)
and Fas ligand (FasL) in NPC survival, differentiation, and T-cell cross-talk in
vitro and in vivo in experimental autoimmune encephalomyelitis (EAE; a wellestablished animal model of MS).
Activation of Fas via FasL increased NPC survival by decreasing
apoptosis (as opposed to increasing proliferation) in vitro. This decreased
apoptosis correlates with upregulation of the inhibitor of apoptosis protein (IAP)
Birc3. Further investigation into the importance of Fas in NPCs was
accomplished by comparing wild-type and Fas-deficient (lpr) NPCs. Lpr NPCs
exhibited decreased apoptosis, decreased proliferation, and increased
differentiation to oligoprogenitor and neuronal lineages. These studies suggest
the Fas system plays multifaceted roles in NPCs and that its exact functions are
dependent on both functional Fas expression and presence or absence of FasL.
To determine the role of Fas/FasL in neuroimmune cross-talk, co-cultures
of wild-type or lpr NPCs with different T-cell subtypes (Th1, Th2, and Th17 cells)
were performed. Th1 cells were the only subtype capable of inducing NPC
apoptosis. Th1-mediated death was dose-dependent and was not mediated via
Fas. On the other hand, NPCs were able to induce significant apoptosis in proinflammatory Th1 and Th17 cells without affecting anti-inflammatory Th2 cells.
NPC-induced Th17 cell death was mediated via Fas. These data suggest NPCs
can specifically target pro-inflammatory T-cells and can promote neuroprotection
by inducing death of these proencephalogenic cells. Finally, intravenous injection
of wild-type or lpr NPCs into EAE mice reduced clinical symptoms and CNS
immune infiltrate to the same extent. Few NPCs enter the CNS, where they
remain undifferentiated. This suggests the main mechanism through which NPCs
produce beneficial results in EAE is via peripheral immunoregulation, which is not
dependent on Fas expression. Overall, this dissertation elucidates the Fas
system as an important modulator of NPC cell-fate and immunoregulatory
capacity.
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CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW

Introduction
Multiple sclerosis (MS) is a chronic neurological disease - affecting a significant
number of young adults – for which new therapies must be developed in order to
alter the usually debilitating disease course. The pathogenesis for this disease is
not completely understood, but autoimmune inflammatory CNS damage lead by
T-cells reactive against myelin protein is the generally accepted hypothesis. The
disease is mediated by various T-cell subtypes that can either tip the balance for
or against neuronal damage. Due to the crucial role T-cells play in the
pathogenesis of MS, immunomodulatory therapies are the main treatment
options for patients. Though currently available treatments are somewhat helpful
in treating disease relapses, they do not prevent the eventual accumulation of
axonal damage and neurodegeneration that ultimately results in irreversible
neurological damage (Myhr, 2008). Neural progenitor cell (NPC) transplantation
has shown promising results in experimental autoimmune encephalomyelitis
(EAE; an animal model of MS), where clinical symptoms have been significantly
decreased or eliminated along with decreased inflammation and axonal damage
on a histological level (Pluchino et al., 2004). Very few transplanted NPCs remain
in the brain and terminally differentiate into oligodendrocytes or glial cells;
however, a more pronounced function of these cells is their immunoregulatory
and neuroprotective functions (Einstein, 2008). Since transplanted NPCs have
1

the ability to migrate to areas of brain inflammation, where they could accelerate
remyelination by inducing growth factor production and activating endogenous
progenitor cells, they represent a logical and innovative therapeutic approach for
development.

The long-term survival of transplanted NPCs needs to be addressed in order for
this treatment option to be viable for a chronic human disease such as MS. One
possible way NPC survival could be enhanced in vitro and in vivo is through
manipulation of receptors or other factors that prevent apoptosis. Fas, a receptor
with well known functions in the immune system but unresolved functions in the
nervous system and NPCs in particular, may be an important therapeutic target.
The importance of Fas/FasL in MS remains unclear because data from Fas
manipulations in EAE have been conflicting – thus, the importance of this factor
in NPCs and MS may need to be elucidated in a more simplified system. The
goal of this dissertation research was to manipulate Fas in vitro, investigate its
importance in the communication between NPCs and T-cells (a mimic of
interactions that occur in MS CNS lesions), and consequently determine if
modulating NPC Fas expression results in enhanced post-transplantation
survival and more effective amelioration of EAE.
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Multiple Sclerosis and the need for improved therapies

The Disease
MS is a chronic debilitating disease characterized by multifocal lesions of the
white matter and a variable clinical course. It is the most common inflammatory
demyelinating disease of the CNS, affecting more than 400,000 people in the US
and 1.1 million worldwide (Noonan et al., 2002). MS is a major public health
issue with a considerably high socio-economic burden. It is predominately a
disease of young adults, and is the main non-traumatic cause of neurological
disability in this age group (Sospedra & Martin, 2005). According to a Department
of Health and Human Services Report (1992), the mean age of death in MS
patients is 13 years younger than the national average. Even more striking is the
profound decreased quality of life MS patients experience (Wynia et al., 2008).
This decreased quality of life is related to the disabilities MS patients experience,
including fatigue, impaired cognitive functioning, depression, and bladder and
sexual dysfunction.
Fatigue is often described by patients as their most disabling symptom
(Chaudhuri & Behan, 2004a). Other common MS symptoms during relapse
include spasticity (hypertonia), ataxia/tremor, double vision, impaired ambulation,
pain, and mood disturbance. Any of these symptoms could persist or gradually
worsen to long-term disability. Additionally, cognitive impairment significantly
affects patients due to memory problems, decreased speed of information
processing, decreased mental flexibility, and impaired executive functioning
3

(Heesen et al., 2010). Certain psychiatric illnesses (major depression, bipolar
disorder, and psychosis) have an increased prevalence among MS patients
compared to the general population (Cerqueira et al., 2010; Sullivan et al., 1995).

MS typically progresses from a relapsing-remitting disease -characterized by
bouts of CNS inflammation - to a chronic-progressive course, wherein the
disease becomes more “neurodegenerative” in nature with mounting axonal
degeneration and neuronal loss (Compston, 2008; Leray et al., 2010). These
presentations of the disease are referred to as relapsing-remitting MS and
secondary-progressive MS, respectively. It has been reported that progressive
accumulation of neurological deficits results in 50% of untreated patients
becoming wheelchair bound after 15 years (Weinshenker, 1995). This highlights
the importance of developing treatments that can effectively combat the
mounting axonal loss and neurogeneration that occurs in later stages of the
disease.
Etiology
Though the cause of MS is still debated, the most prominent, and generally
accepted, theory is that autoreactive T-cells directed against components of
myelin protein cause inflammatory neurological damage. The significant clinical,
genetic, and pathological heterogeneity of the disease indicate that developing
MS may be dependent on multiple pathogenic mechanisms as well as complex
interactions between genetic susceptibilities and environmental insults. The
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genetic basis of MS appears to be uncertain, but strong evidence for a genetic
contribution to the disease comes from family and twin studies (Stern & Keskin,
2008). In several studies, certain genetic “risk factors” such as polymorphisms in
cytotoxic T-lymphocyte antigen 4 (CTLA-4) gene and the human leukocyte
antigen (HLA)-DRB1 haplotype on chromosome 6 have been implicated in
conferring susceptibility to MS (Stern & Keskin, 2008).

Studies have also implicated various environmental factors that may contribute to
susceptibility and disease development (summarized in Table 1). Geographic
differences appear to be important, as the risk of developing MS increases from
south to north (Ebers, 2008). Some of these differences could be contributed to
ethnicity and genetic factors; however, latitude remains the strongest factor for
risk after controlling for other variables (Wallin et al., 2004). Sunlight exposure
and consequent active Vitamin D levels could contribute to the association
between latitude and MS incidence. There is strong evidence for Vitamin D
conferring protection against MS. High dietary consumption of Vitamin D (fatty
seafood, cod liver oil, ect) or vitamin D supplementation are both associated with
decreased risk of developing MS (Kampman & Brustad, 2008; Kassandra et al.,
2006; Munger et al., 2004).

Exposure to certain pathogens as well as metabolic disturbances are suspected
of initiating MS in susceptible individuals (Chaudhuri & Behan, 2004b; Serafini et
5

al., 2007). There is some support for Epstein-Barr virus (EBV) as an
environmental insult that could contribute to MS development in genetically
predisposed people. For example, a higher percentage of MS patients (>99%)
test positive for EBV infection compared to controls (>94%) (Ascherio et al.,
2001). Though this difference is not particularly striking, the level of EBV
antibodies in the blood appears to be important as high titers of EBV antibodies
confers risk of developing MS (Levin & Danesh-Meyer, 2008; Sundström et al.,
2004). Smoking is a significant risk factor for MS development, and this risk has
been shown to be dose-dependent (Hawkes, 2007; Hernán et al, 2001). In a
study of patients diagnosed with clinically isolated syndrome, 75% of smokers
developed MS while only 51% non smokers developed MS after 3 years (Di Pauli
et al., 2008).

6

Table 1-1: Summary of factors that confer protection against or risk for
developing MS

Static Factors

Dynamic Factors

Protective

Protective HLA haplotypes

Outdoor activity/sun exposure
Vitamin D supplements
Diet high in fish oils

Risk Factors

*Adapted from Ramagoplan et al., 2010.

Family history/genetic risk factors
Female sex
Born in high lattitude regions

Exposure to EBV
Smoking
Vitamin D deficiency
Resident in high latitude regions
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The most abundant and compelling data supports an inflammatory autoimmune
process as the major source of pathology in MS. For example, inflammatory
immune cell infiltrates are present in histopathologic MS lesion specimens from
patient autopsies and biopsies (Lucchinetti et al., 2000), the cerebrospinal fluid of
patients with MS have increased oligoclonal IgM and IgG levels compared to
age-matched controls (Link 1987; Villar et al., 2005), T-cells reactive against
myelin have been documented in the brain lesions, cerebral spinal fluid (CSF),
and peripheral circulation of patients with MS (Oksenberg et al., 1993; Zhang et
al., 1994). Additional support for an autoimmune basis of MS comes from studies
that show patients with MS are more likely to have other autoimmune disorders
compared to controls; also, MS - like all other autoimmune diseases - affects
more women than men with a ratio of 1.77 to 1.00. Furthermore, MS lesions
show expression of IL-12, IL-18, and IFN-γ, all of which are markers of proinflammatory T-cell (Th1) activation (Frohman, 2006). A newer line of evidence
suggests certain polymorphisms of the gene encoding IL-7 receptor α -- a
cytokine receptor involved in the differentiation and maintenance of B- and Tcells -- confer risk for developing MS (Gregory et al., 2007; Lundmark et al.,
2007). Therefore, it appears that immune cells and their modulation play a crucial
role in the pathogenesis of MS. Perhaps one of the most convincing arguments
for an autoimmune/inflammatory cell basis of MS comes from the fact that each
of the currently used clinical drugs work by modulating the immune system.
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Current Therapies
All currently available MS therapies exert their effects via immunomodulatory or
immunosuppressive functions. They exhibit efficacy in decreasing the number
relapses, but are unable to prevent or reverse the accumulation of neuronal cell
death and axonal degeneration that results in neurological disability in primary
and secondary progressive forms of the disease. The first FDA approved drug for
MS was IFN-β1b (Betaseron). Other IFN-β preparations are Avonex and Rebif.
The IFN-β drugs are cytokines with the ability to modulate immune
responsiveness, but the precise mechanism of action is not well understood
(Galetta et al., 2002). Another immunomodulatory treatment, glatiramer acetate,
has the ability to shift active T-cell response from the inflammatory Th1 to the
regulatory Th2 phenotype (Steinman, 2005).

Unfortunately, these therapies do not benefit all patients. Long-term studies have
shown IFN-β and glatiramer acetate are only able to reduce the rate of relapse
by 30% (Steinman, 2005). Natalizumab (monoclonal antibody to α4β1 integrin)
interferes with leukocyte adherence to endothelial cells, effectively blocking the
trafficking of pro-inflammatory infiltrates across the blood brain barrier (Myhr,
2008). Use of this drug is controversial and restrained because of multiple cases
of patients developing progressive multifocal leukoencephalopathy (Stüve &
Bennett, 2007). Lastly, novantrone (mitoxantrone) suppresses the production of
pro-inflammatory cytokines and the proliferation lymphocytes and macrophages
(Myhr, 2008). A substantial number of patients require addition of an
9

immunosuppressant (mitoxantrone) along with their primary treatment because
of continued relapses and disease progression.

Overall, the drugs that are currently used have one mode of function (peripheral
immunoregulation), are only useful in relapsing-remitting forms of disease, and
do not prevent long-term disability. There are several novel agents in
development for oral administration (as opposed to above mentioned therapies
which are all parenteral); however, they also target different aspects of the
immune system such as proliferation (Cladribine) or cell trafficking (Fingolimod)
(Krieger, 2011). There is a dire need for developing therapeutics that can directly
influence the CNS. Methods of enhancing remyelination and decreasing axonal
damage (i.e. promoting neuroprotection) will be particularly useful later stages
and primary progressive MS – forms of the disease which are notoriously
resistant to immunotherapies.

Important immune components and concepts in MS
The Road to Damaged Myelin
Exact mechanisms contributing to MS pathology are still debated; particularly the
exact trigger/antigen leading to CNS inflammation remains most elusive. Despite
this, considerable data, both from the EAE murine model and from patient data
supports the following sequence of events contributing to inflammatory infiltration
and CNS tissue damage (See Figure 1-1 illustrating each step).
10

Figure 1-1: Cascade of events leading to CNS damage
T-cells are activated in the periphery by an antigen presenting cell. Autoreactive
T-cells then enter the CNS where they are re-activated and damage the myelin
sheath, exposing neurons to damage, via a variety of mechanisms. Inflammation
is propagated by production of chemokines that recruit additional immune cells to
infiltrate the CNS compartment. Figure courtesy of Dr. Hillel Panitch.
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Peripheral activation (Figure 1-1(1)) of an autoreactive T-cell is considered the
first step. This may occur via a “molecular mimicry” process, where an invading
antigen is similar to a CNS self antigen, causing cross-reactivity. Support for one
specific instigating antigen is lacking, and it has been proposed that the antigen
may actually be different in different individuals or change over the course of time
in one individual and this may contribute to the heterogeneity that exists within
MS. However, there is strong evidence that the antigen is myelin-related. For
example, a study using altered peptide ligands (APLs) met with unexpected
results in clinical trials. Myelin basic protein 83-99 (MBP83-99) was originally
developed in EAE as a therapeutic. It was hypothesized to work by interacting
with the T-cell receptor and reducing the activation of autoreactive T-cells while
increasing the production of regulatory T-cell populations. Phase II clinical trials
of this drug were shut-down due to reports of exacerbation of MS symptoms and
clinical relapse (Martin, 2000). These relapses were preceded by expansion and
activation of MPB-specific CD4+ T-cells in the periphery (Martin, 2000).
Additionally EAE, a model disease induced in animals by injection of various
myelin derivatives, shares important pathological and clinical parallels with MS
(Wekerle, 2008). These provide convincing evidence that immune autoreactivity
to myelin is involved in the pathogenesis of MS.

A peripherally activated T-cell enters the CNS by first adhering to the endothelial
BBB (Figure 1-1(2)). This process occurs via a “rolling” and “tethering” process
12

mediated by selectins and integrins. Endothelial cells in MS lesions express
higher levels of the adhesion molecules intracellular adhesion molecule (ICAM)-1
and vascular cell adhesion molecule (VCAM)-1, and levels correlate with extent
of immune infiltration (Cannella & Raine, 1995; Ransohoff, 1999; Washington et
al., 1994). Their cognate ligands (lymphocyte function-associated antigen [LFA]-1
and very late antigen [VLA]-4) are found on perivascular inflammatory cells (Bö
et al., 1996). Local production of lytic enzymes (i.e. matrix metalloprotenases
[MMPs]) facilitates breakdown of the basement membrane and allows immune
cells to infiltrate the brain parenchyma (Kieseier et al., 1999)(Figure 1-1(3)).

Once the autoreactive T-cell has invaded the CNS, it is reactivated (Figure 11(4)) by an antigen presenting cell (microglia or astrocyte). The entire process
culminates in direct or indirect damage to neurons and oligodendrocytes (Figure
1-1(5)). Myelin sheath destruction leads to transected axons, and ultimately
clinical symptomology in patients. A variety of mechanisms are implicated in CNS
tissue damage, including proinflammatory cytokines, NO-/reactive oxygen
species, glutamate-mediated cytotoxicity, complement fixation, and MMPs (BarOr, 2008). Inflammation-driven tissue damage is perpetuated by production of
chemokines that attract additional infiltrating cells (Figure 1-1(6)). The chemokine
CCL5/RANTES is upregulated at the MS lesion edge (Hvas et al., 1997) and
CCR2 is expressed by local astrocytes (Tanuma et al., 2006). Futhermore, the
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CSF of MS patients contains elevated levels of CXCL10 and CCL5 (Nakajima et
al., 2004; Szczucinski, 2011).
Mediators of Inflammation and Regulation
Just as current MS therapy targets specific immune cells in acute inflammation,
treatment for chronic lesions will have to address specific subpopulations of Tcells. Both CD8+ and CD4+ T-cells are visualized in acute inflammatory lesions
and to a lesser extent in chronic demyelinated lesions (Stadelmann & Brück,
2008). CD4+ and CD8+ T-cells are activated by major histocompatibility complex
type II (MHC-II) and MHC-I molecules, respectively. Based on several genetic
risk studies, MHC-II alleles confer the largest risk for MS (Oksenberg & Hauser,
2005). Furthermore, CD4+ T cells are the main mediators of MS pathogenesis
(Bar-Or, 2008; Lutton et al., 2004). Therefore, I focus on CD4+ T-cell subsets in
my study.

Naïve CD4+ T-cells differentiate into 4 distinct subsets: Th1, Th17, Th2, and Treg
(illustrated in Figure 1-2). This differentiation is highly dependent on the cytokine
milieu (Dittel, 2008). For instance, IL-12 is required to produce Th1 cells, while
the presence of IL-4 is needed for Th2 cells. TGF-beta is essential for the
generation of both Treg and Th17 cells, but the addition of IL-6 is needed for
creating Th17 cells. Exposure to different cytokines leads to the expression of
transcription factors specific to each respective lineage (Figure 1-2).
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TGF-β
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STAT3
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IL-10

IL-17

pro-inflammatory

anti-inflammatory

Figure 1-2: The major CD4+ Subtypes
Upon appropriate stimulation (often CD3/CD28), a naïve T-cell differentiates into
one of several subsets, dictated by the cytokine milleu. Shown are cytokines
required for production of each subset. Each CD4+ subtype is characterized by
the cytokines they produce. Cells producing anti-inflammatory cytokines are
shown in GREEN and those producing pro-inflammatory cytokines are shown in
RED. To further differentiate these cells, each subtype also has unique
expression of transcription factors (shown below each cell type within the “cell”).

15

Furthermore, these T-cell subtypes are categorized by the type of cytokines they
produce (Hedegaard, 2008). Th1 cells are characterized by production of IFNgamma and TNF-alpha (pro-inflammatory), while Th2 cells manufacture IL-4
(anti-inflammatory).

Th1 and Th-17 cells are most likely the main inducers of disease activity
(McFarland & Martin, 2007). Production of IFN-γ by Th1 cells and IL-17 by Th17
cells are thought to be the main mediators of autoimmune destruction in MS
(McFarland & Martin, 2007). One of the functions of IFN-γ is the activation of proinflammatory macrophages which drive chronic inflammation and tissue injury.
Immunohistological investigations of CNS tissues at the height of disease in
animal models show high levels of TNF-alpha and IFN-gamma (Khoury et al.,
1992). Comparatively, levels of these factors are relatively low in recovery
stages. Furthermore, transfer of reactive Th1 cells alone is sufficient to induce
EAE (Baron et al., 1993; van der Veen et al., 1993). Because of this evidence,
dysregulated Th1 functions have been historically viewed as responsible for the
autoimmune damage that occurs in MS. However, studies showing mice
genetically deficient in IFN-γ not only develop EAE, but exhibit a more severe
disease course (Ferber et al., 1996) seriously challenged this established
concept.
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The importance of Th17 cells in MS pathogenesis has more recently been
appreciated (Aranami & Yamamura, 2008), and knowledge of this subtype has
filled critical holes in MS immunological dogma. These cells produce IL-17, a proinflammatory cytokine that induces the production of chemokines and
metalloproteinases which promote propagation of inflammation and tissue
damage, respectively. IL-17 is clearly important in EAE pathogenesis because
mice deficient in this cytokine have an attenuated disease course (Komiyama et
al., 2006). Likewise, administering antibodies against IL-17 helps prevent
development of disease and delays onset of paralysis upon EAE induction (Park
et al., 2005). Moreover, elevated IL-17 levels are found in the blood, CSF, and
active lesions of MS patients (Matusevicius et al., 1999; Tzartos et al., 2008).

Studies of IL-23 help solidify the importance of the Th17 subtype in MS
pathogensis. IL-23 is required as a growth and maturation factor of pathogenic
Th17 cells (McGeachy & Cua, 2007). IL-23 has a unique p19 subunit and shares
the p20 subunit with IL-12 (required for Th1 maturation); however, genetic
manipulation of these two genes in EAE produces very different results. IL-23p19
deficient mice are completely resistant to developing EAE, whereas mice
deficient in IL12 are susceptible (Cua et al., 2003). Highlighting the importance of
IL-23, its production is higher in dendritic cells from MS patients compared to
healthy controls (Vaknin-Dembinsky et al., 2006). Furthermore, IL-23p19 is
expressed in both active and chronic lesions (Li et al., 2007).These findings
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suggest IL-23 is pivotal in augmenting the inflammatory response and
consequently contributes to CNS damage. Finally, IL-6 (another cytokine critical
to Th17 production) gene transcripts are higher in the brain tissue of MS patients
(Lock, 2002) and treatment with an IL-6R antibody ameliorates EAE (Serada et
al., 2008).

Both Th2 and Treg cells are thought to have overall protective roles in MS. Th2
cells are regarded as beneficial in the context of MS lesions and play a protective
role in EAE (Liblau et al.,1995). For example, IL-4 secreted by Th2 cells prevents
re-induction of active EAE in recently recovered animals and Th2 cells perform
as robust inhibitors of encephalitogenic Th1 cells in vitro (Liblau, et al., 1995; van
der Veen, et al., 1993). The extent of inflammation in MS is controlled by the upand down-regulation of CD4+ cells (Dittel, 2008). Specifically, Treg cells have the
ability to suppress the functions of other T-cells, down-modulate inflammation,
and protect brain tissue in this process by balancing CD4+ Th1 and Th2 subtypes
(Dittel, 2008). Deficiency of Treg cells predisposes animals to developing organspecific autoimmune disease (Thornton & Shevach, 2000). Treg cells exert some
of their anti-inflammatory effects via production of IL-10 (also produced by Th2
cells), which has the ability to regulate the expression of cytokines and antigen
presentation molecules (Selvaraj & Geiger, 2008; Stern et al., 2008). Studies in
EAE suggest IL-10 protects against compromise of blood brain barrier (Dittel,
2008). On a clinical level, T-cell cultures from MS patients in remission produce
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higher amounts of IL-10 relative to either MS patients in relapse or healthy
controls (Correale et al., 1995). Other mechanism for Treg inhibition of reactive
T-cells includes cytotoxic T-lymphocyte antigen-4 expression, TGF-beta
production, costimulatory molecule blockade and direct T-cell interactions
(Shevach et al., 2001). Passive transfer of Treg cells protects against EAE
whereas deletion of CD25+ Treg cells increases the severity of EAE (McGeachy
et al., 2005; Yu et al., 2005). Levels of Treg cells are equivalent in MS patients
and healthy controls, but the ability of MS patients’ Treg cells to inhibit myelinresponsive inflammation is reduced (Haas et al., 2005; Venken et al., 2008).
Thus, Treg functions are clearly important in down modulating inflammation and
consequently mediating clinical remission.

Treg cells function to control a delicate balance between avoiding autoimmune
disease and allowing overt autoinflammatory responses, apparently required for
promoting neuroprotection and repair, to occur. For instance, in rats with induced
optic nerve or spinal cord damage, lack of Treg cells serves to enhance
spontaneous T-cell inflammatory responses and consequent post-injury neuronal
survival; however, increasing the number of Treg cells has an opposite “proneuronal injury” effect (Kipnis et al., 2002). So, Treg cells are very efficacious at
decreasing the inflammatory processes that lead to damage in MS, but excess
numbers of Treg cells may actually prevent inflammation-mediated brain repair.
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Neuroprotective Autoimmunity
In general, it is thought that inflammatory processes in the brain are detrimental;
however, recent evidence suggests autoimmune inflammation can promote CNS
protection and repair processes like remyelination (Kerschensteiner et al, 2003).
This concept of “neuroprotective autoimmunity” is important to consider in the
pathogenesis of MS since autoimmune processes, which clearly play a role in
initiation of the disease process, also have the potential to be beneficial and
decrease neuronal injury.

There are several lines of evidence that support the idea that inflammation after
CNS injury can have beneficial side-effects. In rodents, the transfer of myelinreactive T-cells reduces post-injury neuronal loss relative to controls (Butovsky et
al., 2001; Hauben et al., 2000; Moalem et al., 2000). For example, in optic nerve
crush injury experiments, secondary degeneration of neurons is decreased when
animals are treated with T-cells directed against myelin epitopes (Moalem et al.,
1999; Schwartz et al, 1999). Importantly, immunodeficient animals have
diminished capacity to recover from damage to the nervous system (Serpe et
al.,1999; Serpe et al., 2002). Furthermore, animals lacking endogenous T-cells
suffer worse CNS injury compared to wild-type animals (Kipnis et al., 2001; Yoles
et al., 2001). In a mouse model of lysolecithin-induced demyelination, Rag-1deficient mice (CD4+ and CD8+ depleted) fail to remyelinate (Beiber, 2003), thus
supporting the view that functional T-cells are central to remyelination processes.
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The exact mechanism for how inflammatory cells can mediate neuroprotection
remains to be discovered. One possible way of facilitating this process could be
through the production of neurotrophic factors. Immune cells are known to
produce both BDNF (shown to be expressed in inflammatory brain lesions of MS
patients) and NGF (Kerschensteiner, et al., 2003). Myelin-reactive T-cells home
to sites of injury and have been implicated in upregulating the production of
GDNF, NGF, NT3 and anti-thrombin III (Schwartz, 2001).

The factors important in regulating a dual or “two-faced” role of autoimmunity -where autoimmune inflammation is responsible for significant tissue damage, but
is also required for repair processes occur -- are only beginning to be defined. As
an example of the dichotomous role of immunity, IFN-γ is undoubtedly a major
player in destructive inflammatory processes, but this cytokine also enhances
microglial clearance of glutamate in response to damage – a necessary step in
repair processes (Shaked et al., 2005).

Introduction of exogenous NPCs to inflammatory lesions have shown potential
for promoting the beneficial effects of the immune response. For example,
transplanted adult NPCs and inflammatory cells (T-cells and microglia) work
synergistically to promote neurogenesis and functional recovery in spinal cord
injury (Ziv et al., 2006). Moreover, NPC transplantation has the ability to reduce
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the number of pro-inflammatory T-cell perivascular infiltrates and increase the
proportion of Treg cells (Einstein et al., 2006), thus in two respects they can
function to down-regulate inflammation. Elucidating the effects of separate T-cell
populations on NPCs is important in the context of transplantation therapies as
well as promotion of remyelination by endogenous oligo- and glial- progenitors
that reside in the CNS.

Progress and Promise of Neural Stem Cell Therapies
NPCs are a heterogeneous population of self-renewing and multipotent cells
(Martino & Pluchino, 2006). They can proliferate almost indefinitely in serum-free
cultures supplemented with EGF and FGF, but when growth factors are
withdrawn, they will spontaneously differentiate into neurons, astrocytes, or
oligodendrocytes (post-mitotic daughter cells) (Galli et al., 2003). In suspension,
NPCs form characteristic free-floating neurospheres (non-adherent spherical
aggregates of cells), but they can also be grown as proliferating single cells in a
supporting matrix monolayer (Galli et al., 2003). At the beginning of the 20th
century, the observations of Cajal lead him to distinguish between the developing
and mature CNS on the basis of the adult CNS lacking the ability to regenerate
(Cajal, 1928). However, he did speculate there was some limited capacity for
regeneration. For the majority of the 20th century, it was thought that the adult
CNS was static, and any brain injury would be doomed to persist without repair.
In the late 1960s, the observation of proliferating neural cells in the adult rat brain
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made the possibility of CNS regeneration more feasible (Altman, 1969; Altman &
Das, 1965). It is now recognized that neural stem/progenitor cells reside in the
adult CNS and support neurogenesis and gliogenesis throughout life (Reynolds
and Weiss, 1992; Pluchino & Martino, 2008). NPCs reside in definitive
germinative zones in the developing and adult CNS and as such they can be
isolated from embryonic, fetal or adult tissues (Martino & Pluchino, 2006). The
main niches of NPCs in the adult are the subventricular zone (SVZ) of the lateral
ventricles and the subgranular zone of the hippocampal dentate gyrus (Pluchino
& Martino, 2008).

Though remyelination occurs throughout the course of MS, ultimately the
endogenous supply of NPCs fails to promote full and long-lasting repair (Pluchino
et al., 2004).This may be due to a derangement of normal sub-ventricular zone
progenitor cell proliferation and differentiation by inflammation (Pluchino &
Martino, 2008). A possible mechanism for this disruption of normal NPC
physiology could be the production of stem cell regulators – such as BMP4 or
noggin – and/or cytokines from infiltrating immune cells and reactive CNSresident cells (astrocytes, microglia, and brain endothelial cells). Support for this
theory comes from observations that overall remyelination in periventricular
regions – the main location of inflammatory CNS lesions in MS - is lower than
other brain areas (Patrikios et al., 2006) and areas of demyelination contain
oligodendrocyte precursors without signs of remyelination (Chang et al., 2002).
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Inadequate remyelination leaves axons susceptible to injury or elimination in the
destructive MS lesion environment. Since axonal damage is one of the most
important pathological events related to neurological disability in MS, developing
methods to protect axons by enhancing remyelination is a major direction of
current research. Transplantation of cells with neuroprotective potential into the
damaged adult CNS provides possibility for bypassing the limited capacities of
endogenous cells. Furthermore, since inflammation likely disrupts the structural
and functional integrity of progenitor germinal centers in the brain, introducing
exogenous NPCs in MS may be more efficacious than protocols aimed at
activating endogenous stores of NPCs.

The development of neural stem cell transplantation therapy holds potential for
many neurodegenerative diseases for which there is no currently effective
treatment – the paradigmatic disease being MS (Pluchino & Martino, 2005;
Rosser et al., 2007). Multiple groups have concluded that transplanting NPCs
into EAE animals results in reduction of inflammation, decreased demyelination
and axonal damage, and consequent improved clinical outcomes (Einstein et al.,
2003; Pluchino et al., 2003; Politi et al., 2007). Clear therapeutic effects were
observed in both chronic-progressive and relapsing-remitting EAE. Intravenously
and intraventricularly injected NPC are able to migrate specifically to inflamed
areas of the CNS (Pluchino, et al., 2003). Acute inflammatory lesions attract and
maintain transplanted cells, allowing for NPC to exert their neuroprotective
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effects (Ben-Hur et al., 2003). This homing is due to NPC expression of highaffinity cell adhesion molecules (such as CD44, VLA-4) and functional chemokine
receptors, which allow them to utilize the same pathways that immune cells travel
when invading the inflamed CNS (Pluchino & Martino, 2005). With expression of
these molecules, NPCs are able to follow a cytokine gradient -- in either CSF or
blood – that leads them to sites of CNS inflammation. Highlighting the importance
of these mechanisms, when NPCs are pre-treated with VLA-4 neutralizing
antibody before transplanting, only 5% of transplanted NPC home to inflamed
regions of the CNS (Pluchino et al., 2005).

Though originally pursued as a cell-replacement strategy, transplanted NPCs
appear to exert their therapeutic effects mostly through bystander
neuroprotective and immunoregulatory functions. I will discuss the
neuroprotective bystander functions of NPCs here, and cover their robust
immunomodulatory capacity in the next section (“The neuro-immune interface”).
Most transplanted cells retain an undifferentiated phenotype, so it is rare for them
to terminally differentiate and replace lost neural cells. Pluchino’s work showed
only 10-15% of injected NPCs became positive for oligodendrocytes markers
(Pluchino et al., 2003); therefore, most remyelination that occurs in these EAE
transplant models must be carried out by endogenous cells. Transplanted NPCs
appear to exert their neuroprotective effects via a bystander mechanism wherein
released neurotrophic factors (NGF, BDNF) facilitate endogenous neuronal
25

health (Martino & Pluchino, 2006). Specifically, transplanted NPCs can foster
remyelination driven by endogenous oligodendrocytes and decrease astrogliosis.
Furthermore, neurotrophic factors released by NPC promote axon growth when
introduced into a co-culture system with dissected brain cortex and spinal cord
(Kamei et al., 2007).

A major issue in transplantation therapy is the long-term survival of stem cells in
the adult CNS. Individual precursor cells do not survive well in the adult brain,
presumably because levels of required growth and trophic factors, such as
epidermal growth factor (EGF) and fibroblast growth factor (FGF), are not
sufficient (Einstein et al., 2006). In vivo survival of NPCs is drastically improved in
the EAE model when transplanted as neurospheres. Neurospheres grown from
adult NPCs can survive for up to 2 months in the CSF of mice, possibly because
of their ability to create a self-sustaining microenvironment by producing trophic
signals (Einstein et al., 2006). However, the longer term survival of neurospheres
is as yet unknown. Because of their large size and heterogeneous makeup,
translation into humans may be more difficult than dissociated single-cell
therapies. In rat models, oligodendrocyte precursor cells are unable to survive
upon transplantation into a healthy/normal CNS environment (Franklin et al.,
1996; O'Leary & Blakemore, 1997). However, survival of OPCs is dramatically
improved when transplanted during an active inflammatory process (Tourbah et
al., 1997). It has been further established that acute lesions can both attract and
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prolong survival of transplanted cells (Ben-Hur et al., 2003; McDonald et al.,
1999; Modo et al., 2002). In chronic diseases, such as MS, transplanted cells
would need to survive during both remission and relapsing stages of the disease
in order to be an effective treatment. Therefore, elucidating strategies for
promoting NPC survival in a growth factor-poor environment is critical for
advancing transplantation therapies. The exact mechanisms responsible for
increased progenitor cell survival in the presence of inflammation remain
unknown.

The neuro-immune interface
It is well established that one of the main effects that transplanted NPCs exert is
“bystander” immunomodulation (Ben-Hur, 2008; Einstein & Ben-Hur, 2008;
Fainstein et al., 2008; Pluchino & Martino, 2008). However, the exact factors that
contribute to NPC immunomodulatory capacity are unknown. Considering that
the interactions between immune cells and NPCs (among other resident CNS
cells) is critical in both pathology and repair processes in MS, a full
understanding of the critical pathways that influence NPC/T-cell interactions is
important for developing novel therapies.

Places of possible interaction for these cell types include the CNS and the
periphery. As mentioned above, injected NPCs have the ability to home to sites
of CNS inflammation where they can modulate inflammation and repair
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processes directly. Injected NPCs reduce CNS inflammation, axonal injury, and
demyelination. One of the ways NPCs down-modulate inflammation, and
consequently reduce CNS tissue damage, is by inducing pro-inflammatory Th1
cell apoptosis (Pluchino et al., 2005). Transplantation of adult NPCs into EAE
mice significantly decreased the number of inflammatory CNS infiltrates and
increased the number of TUNEL positive encephalitogenic T-cells by 3-fold.
These effects are attributed to upregulation of death receptor ligands (FasL, Trail,
and APO3) on NPCs upon exposure to pro-inflammatory cytokines produced by
Th1 cells. Furthermore, blockade of the death receptor pathways significantly
decreased the in vivo and in vitro apoptosis of reactive Th1 cells. Therefore,
NPC-induced Th1 cell death mediated via death receptors such as Fas helps
shift toward a more favorable Th2 dominated environment; thus, resulting in
reduced brain inflammation (Pluchino et al., 2005). It has also been shown that
NPCs inhibit T-cell proliferation by both producing and inducing T-cell upregulation of NO and prostaglandin E2 (Wang et al., 2009).

In addition to central effects, intravenously administered NPCs can interact with
T-cells in lymph nodes and help attenuate EAE by decreasing peripheral T-cell
activation (Einstein et al., 2007; Pluchino et al., 2009). Co-culture experiments
showed NPCs have the ability to inhibit lymph node derived T-cell proliferation in
response to either polyclonal or CNS-derived antigens (Einstein, et al., 2007).
EAE mice injected subcutaneously with NPCs (in order to target lymph nodes)
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show significant clinical improvement compared to controls (Pluchino et al.,
2009). These results are similar for mice injected either intravenously or
intraventricularly. Subcutaneously injected NPCs are able to modulate EAE by
inhibiting the activation of myeloid dendritic cells as well as hindering the
expansion of encephalogenic T-cells (Pluchino et al., 2009). Further supporting
the peripheral immuoregulatory role of NPCs, human NPCs transplanted into a
primate EAE model inhibited dendritic cell activation and presentation as well as
reduced IFNγ production (Pluchino et al., 2009). Though the immunomodulatory
capacity of NPCs is clear, the exact mechanisms regarding process are just
beginning to be uncovered. Elucidating the factors important in NPC-mediated
immunoregulation is a critical step toward advancing NPC transplantation
therapies.

Additionally, specific T-cell influences on NPC -- which I propose to investigate -have not yet been uncovered. Data on the ability of T-cells to directly influence
NPCs is rare in the literature. Repeated bouts of inflammation can alter
endogenous NPC niche architecture and the ability of NPCs to migrate in vivo
(Pluchino et al., 2008), and pro-inflammatory cytokines inhibit NPC proliferation
in vitro (Ben-Hur, et al., 2003). These reports are limited to the general capacity
of an inflammatory environment to modulated NPCs, and do not decipher direct
effects of T-cells themselves, or difference between T-cell subtypes. My
dissertation focuses on these unanswered questions. Therefore, my research
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complements and expands upon previous studies that have focused on the
ability of NPC to modulate immune cells. Overall, keeping in mind that neuralimmune communication is a two-way street will contribute to a more thorough
understanding of MS pathogensis and new therapeutic targets.

The Fas system: known, unknown, and debated
Fas - also known as Apo-1 or CD95 - is a member of the tumor necrosis factor
(TNF) receptor superfamily. Fas has served as a paradigmatic death-receptor for
elucidation of cell death-induction via the extrinsic pathway (Krammer, 2000).
Therefore, the pathway and regulation of Fas-induced apoptosis is fairly well
characterized. Activation of Fas via its cognate ligand, FasL, results in
oligimerization of the receptor and assembly of the death inducing signaling
complex (DISC) (Wajant, 2002). Contained in the DISC is Fas-associated death
domain protein (FADD) and caspase-8. Proteolytic activity of the DISC complex
results in the activation of caspase-8, which consequently activates (either
directly or indirectly, depending on the type of cell) caspase-3, the effector
caspase. The main regulatory molecule of this pathway is FLIP (FADD-like
interleukin-1β-converting enzyme (FLICE)-like inhibitory protein). FLIP can be
incorporated into the DISC and disable the processing and release of caspase-8
(Peter & Krammer, 2003). The transcription of FasL itself, which is inactive in
most cells, is another way that Fas/FasL effects are regulated. Though Fas is an
ubiquitous receptor, T-cells are the major expressors of FasL (Wajant, 2002).
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Fas is a well characterized death-inducer in the immune system (Krammer, 2000;
Nagata & Golstein, 1995), wherein homeostasis (e.g. elimination of autoreactive
T-cells) is maintained via Fas-mediated apoptosis– yet, multiple studies indicate
this receptor has cell-specific effects that are unrelated to cell death. In fact, even
within the immune system, the functions of this receptor seem to be diverse
given that Fas-mediated proliferation and activation of T-cells has been reported
(Alderson et al., 1993; Siegel et al., 2000; Wajant et al., 2003). As an example of
the heterogeneous, non-immune functions of this receptor, human brain
endothelial cells are resistant to FasL-induced cell death and triggering the
receptor induces release of matrix metalloproteinase-9 (Wosik et al., 2007).
Furthermore, several studies have indicated that the Fas-mediated cell death
pathway is not operational in NPCs (Brunlid et al., 2007; Ceccatelli et al., 2004;
Tamm et al., 2004). Specifically, Ceccatelli’s group found that NPCs undergo
mitochondrial-mediated cell death in response to oxidative stress, while treating
cells with an agonistic Fas monoclonal antibody did not induce apoptosis.
Primary adult NPCs isolated from the subventricular zone of rat brains and a
neural stem cell line C17.2 were used in these studies (Ceccatelli et al., 2004).
Similarly, exposing immature and neurally differentiated murine embryonic stem
cells to soluble FasL did not induce apoptosis (Brunlid et al., 2007). Although it
has been previously reported that NPCs express the Fas receptor, and that
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activation does not result in apoptosis (Ceccatelli et al., 2002), the exact roles of
Fas in NPC biology has not been elucidated.

It is possible that the role of Fas changes depending on the developmental stage
and proliferative properties of neurons and stem cells. For example, Fas plays a
critical role in regulating programmed cell death during embryonic development
of the nervous system because of its expression during critical periods of
neuronal apoptosis and differentiation (Cheema et al., 1999; C. Park et al., 1998;
Raoul et al., 1999). Also, studies have shown Fas is involved in developmental
neuronal death in both motor neurons (Nat et al., 2001) and cortical neurons (van
Landeghem et al., 2002). However, Fas can mediate proliferation and
regeneration of primary sensory (dorsal root ganglion) neurons by activating
extracellular-signal related kinase (ERK) and upregulation of p35 (Desbarats et
al., 2003). Further characterizing the role of this system in neuronal development,
Fas appears to regulate neuronal branching in hippocampal neurons since mice
deficient in Fas or FasL have a normal neuronal number, but exhibit decreased
dendritic branching in hippocampal pyramidal cells (Zuliani et al., 2006). Thus,
Fas appears to have an important and multifaceted role in neuronal
development. Different from Ceccatelli’s observations mentioned above, one
study found that Fas activation - using a monoclonal antibody to Fas - induced
apoptosis in NPCs isolated from 15 day-old mouse embryos (Semont et al.,
2004). These results appear contrary to studies demonstrating that a Fas32

dependent apoptosis pathway is not functional in various types of neural stem
cells. Although the reasons for these differences are unclear, they may be related
to the original cell source, capacities of ESCs compared to NPCs (e.g. pluripotent
versus

multipotent),

culture

maintenance

and/or

treatment

conditions.

Furthermore, Fas may play an evolving, pluripotency-dependent role in
maintenance of the CNS.

EAE: the perfect imperfect model to examine the role of Fas in Multiple
Sclerosis
As with other diseases, an animal model is required to elucidate important factors
that contribute to MS pathogenesis, and thus determine therapeutic targets. EAE,
first described over 70 years ago, is the most well-established and studied animal
model of MS. It has served as the main avenue for determining the current
dogma of the phathophysiological basis of MS as an autoimmune inflammatory
disease instigated by myelin reactive Th1 T-cells. A group in the 1920’s observed
significant CNS inflammation after inoculating rabbits with a human spinal cord
preparation, and thus originated EAE (Gold et al., 2006). The first description of
EAE came almost 10 years later in monkeys that had been repeatedly injected
with rabbit brain extracts in an attempt to reproduce encephalitic complications of
the anti-rabies vaccine (Rivers, 1993). In the years since, EAE has been
reproducibly elicited in a variety of species ranging from rats to sheep to
marmosets (Gold, et al., 2006). EAE exhibits many of the clinical,
neuropathological and immunological aspects of multiple sclerosis (Wekerle,
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2008). For example, EAE is characterized histopathologically by focal areas of
inflammation/demyelination and clinically by ascending paralysis involving the tail
and limbs. A variety of methods exist for induction of EAE. Inoculation with crude
CNS tissue homogenates or with one of several different components of myelin
(myelin basic protein (MBP), proteolipid protein (PLP), or myelin oligodendrocyte
glycoprotein (MOG)) is able to produce an immune response resulting in the
prototypical symptoms of EAE (Steinman & Zamvil, 2005). MOG is considered a
unique autoantigen because of its ability to induce a demyelinating autoantibody
response in addition to the classic encephalitogenic T-cell response (Gold, et al.,
2006). In addition to choice of inoculum, to enhance the immune response and
hasten induction, researchers use oil-based Freund’s adjuvant supplemented
with heat-inactivated mycobacteria tuberculosis (complete Freund’s adjuvant,
CFA). The defined disease activity varies with method of inoculation and species
type. Induction using PLP in PL/J mice results in relapsing EAE, while MOG
induces a chronic progressive course C57/BL6 mice and CNS tissue
homogenate or MOG induces relapsing-remitting disease in Biozzi ABH mice
(Gold, et al., 2006).

Though EAE has parallels with MS, there are multiple differences between the
two, and consequently, several pitfalls to this animal model. For instance, MS is a
spontaneous disease, while EAE is actively induced by sensitization with brain
tissue antigens. It is possible that this artificial induction of a myelin-specific
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immune response may circumvent integral pathologic processes at work in
human disease (Friese et al., 2006). Furthermore, most protocols for EAE
induction use strong immune adjuvants (mentioned above) to boost the immune
system, and it is very questionable whether a similar immune boost could occur
under natural conditions in humans, even in the case of infection (Friese et al.,
2006). Also, EAE is studied in genetically homogenous populations, so the
genetic heterogeneity that contributes to variability of presentation, course, and
pathology in humans cannot be imitated. Perhaps, most importantly, some
treatments showing efficacy in EAE have failed or worsened symptoms in MS
(Steinman & Zamvil, 2005). Even with its faults, EAE is still the main and most
well characterized animal model of MS and as such is valuable in deciphering the
principal factors that contribute to the pathogenesis of the disease – including a
role for the Fas system.

Before discussing in detail the findings Fas studies in EAE, it is worth mentioning
current studies in MS patients. Human data on the significance of Fas is scarce,
but the few studies that do exist suggest there are perturbations of this receptor
that result in resistance to apoptosis and therefore prolonged life in
encephalitogenic T-cells. One study of peripheral blood mononuclear cells
(PBMCs) from MS patients found decreased Fas expression specifically in CD4+
T-cells expressing CCR5. CCR5 is a chemokine receptor highly expressed in
perivascular CNS infiltrating T-cells and implicated in MS (Julià et al., 2006). A
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separate study examining the gene expression profile of PBMCs found that the
negative regulator of Fas-induced apoptosis (TOSO) was upregulated in cells
collected from MS patents compared to age- and sex-matched controls (Achiron
et al., 2007). These studies suggest dysregulation and decreased expression of
Fas in the lymphocytes of MS patients plays a role in protecting pathogenic Tcells and, consequently, contributes to the disease process.

Investigations into the effects of FasL administration or neutralization on EAE
outcomes have been contradictory. Intrathecally administered recombinant FasL
(before disease onset) appears to result in a dose-dependent suppression of
EAE along with lessened pathological inflammation upon histological analysis
(Zhu et al., 2002). Zhu et al. suggested this protective effect stemmed from
infused FasL preventing initial infiltration of T-cells and macrophages into the
CNS. Contrary to these results, intracerebroventricularly administered FasL did
not affect EAE clinical scores, and subcutaneous administration of FasL
significantly worsened EAE (Ciusani et al., 2001). Differences in outcomes could
be attributed to site/mode of administration, sex differences, and method of EAE
induction. Therefore, net beneficial effects, or appropriate route of FasL
administration for alleviating EAE remains to be ascertained. In an alternative
approach, Wildbaum et al. performed a neutralizing study using autoantibodies
against endogenous FasL. Injection of anti-FasL antibodies resulted in significant
protection when administered at the onset of EAE, but actually prevented
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spontaneous recovery when administered after the peak of the acute phase of
the disease (Wildbaum et al., 2000). These results suggest Fas plays
complicated, stage-dependent roles in EAE – where Fas may initially contribute
to CNS damage, but an active Fas system must be present for the clearing
inflammatory T-cells and consequent remission.

The role of the Fas system in EAE has been investigated in mice carrying
autosomal recessive mutations for Fas (lpr) and FasL (gld). Lpr mice have a
retroviral insertion of poly(A) adenylation signal repeats in the gene for Fas
(Nagata & Suda, 1995). This large insertion results in improper splicing and
truncation of Fas mRNA so that the cells are devoid of protein expression. In gld
mice, there is a point mutation in the gene encoding FasL which disables its
ability to interact with and activate Fas (Nagata & Suda, 1995). The development
of both lpr and gld mice is normal, but as the mice age they are prone to
developing lymphoproliferative disease and/or a spontaneous autoimmune
syndrome with similarities to systemic lupus eyrthematosus (Cohen & Eisenberg,
1992). The data from EAE induction in these Fas or FasL deficient animals is as
varied and conflicting as the studies mentioned above. Comparison of wild-type
mice to lpr and gld mice revealed these mutations resulted in relative resistance
to developing EAE (Waldner et al., 1997). Similarly, Okuda et al. found the
frequency of induced EAE in lpr mice was 19% compared to 94% in wild-type
mice (Okuda et al., 1998). However, the role of Fas in development of EAE is not
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so simple, as other reports show either no difference or significantly worsened
EAE clinical symptomology (Dittel et al., 1999; Suvannavejh et al., 2000). In a
study by Dittel et al. EAE induction in lpr, gld, and wild-type mice all resulted in
similar disease scores, suggesting Fas/FasL has little importance in the
generation of EAE (Dittel et al., 1999). Contrary to all these studies, Suvannavejh
et al. found that EAE induction in lpr mice resulted in significantly worsened
disease - as defined by mean peak clinical scores, reduced remission rates, and
increased mortality compared to controls (Suvannavejh et al., 2000). As before,
these studies vary in their use of mouse strain and induction method for EAE.
Overall, Fas/FasL most likely plays a significant role in pathogenesis and course
of EAE, but before this importance can be established, more standardized
approaches to investigating the lpr and gld models will need to be undertaken.
Other options include using a more simplified, in vitro system where variables
can be more tightly manipulated, or cell-specific ablation of Fas (both will be
explored in this thesis).

Summary
Ultimately, elucidating the signals involved in the cross-talk that occurs within MS
lesions should eventually allow us to manipulate various aspects in order to tip
the balance in favor of brain repair. Although NPC have shown clinical efficacy in
animal models and the immunoregulatory functions of NPC have been
established, the critical mediators responsible for this bystander effect are not
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well understood. Furthermore, the specific effects of T-cells on NPCs remain
unexplored. Finally, NPC survival and differentation post-transplantation are
important challenges that need to be addressed before NPC transplantation
therapy becomes a viable therapeutic option.
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Abstract

Though there is a sizable amount of research focusing on adult neural progenitor
cells (NPC) as a therapeutic approach for many neurodegenerative diseases
including multiple sclerosis, little is known about the pathways that govern NPC
survival and apoptosis. Fas, a member of the death receptor superfamily, plays a
well characterized role in the immune system but its function in neural stem cells
remains uncertain. Our study focuses on the effects of Fas on NPC survival in
vitro. Activation of Fas by recombinant Fas ligand (FasL) did not induce
apoptosis in murine NPCs in culture. In fact, both an increase in the amount of
viable cells and a decrease in apoptotic and dying cells were observed with FasL
treatment. Our data indicates FasL-mediated adult NPC neuroprotection is
characterized by a reduction in apoptosis, but not increased proliferation. Further
investigation of this effect revealed that the anti-apoptotic effects of FasL are
mediated by the upregulation of Birc3, an inhibitor of apoptosis protein (IAP).
Conversely, the observed effect is not the result of altered caspase activation or
FLIP (Fas-associated death domain-like interleukin-1beta-converting enzyme
inhibitory protein) upregulation, which is known to inhibit caspase-8 mediated cell
death in T-cells.

Our data indicates murine adult NPCs are resistant to FasL induced cell death.
Activation of Fas increased cell survival by decreasing apoptosis through Birc3
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upregulation, a member of the IAP family of proteins. These results describe a
novel pathway involved in NPC survival.
Introduction
Neural progenitor cell apoptosis is significant in a variety of central nervous
system (CNS) diseases ranging from Alzheimer’s disease to Multiple Sclerosis
(Camins et al. 2008; Haughey et al. 2002; Sohur et al. 2006). Fas (a member of
the TNF death receptor superfamily) is known to contribute to the maintenance of
lymphocyte homeostasis and the deletion of autoreactive T-cells (Nagata &
Golstein, 1995). The clinical effects of stem cell therapy in experimental
autoimmune encephalomyelitis (EAE - the animal model of MS) are mediated by
the induction of pro-inflammatory Th1 apoptosis via the Fas pathway by NPCs
(Pluchino et al., 2005). However, the role of Fas/FasL in adult NPC physiology
remains unknown.

Fas is believed to play a critical role in regulating programmed cell death during
embryonic development of the nervous system because of its expression during
critical periods of neuronal apoptosis and differentiation (Cheema et al., 1999;
Park et al., 1998; Raoul et al., 1999). Fas is involved in developmental neuronal
death in both motor neurons (Nat et al., 2001)

and cortical neurons (van

Landeghem et al., 2002). Recent studies have also implicated Fas involvement in
cell processes other than cell death. A study investigating apoptosis in adult
neural stem cells and a neural stem cell line (C17.2) found that the mitochondrial
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pathway was active, but Fas-dependent cell death was not operational
(Ceccatelli et al., 2004). Desbarats and colleagues have demonstrated that Fas
can mediate proliferation and regeneration via the ERK pathway in neurons
(Desbarats et al., 2003). Further characterizing the role of this system in neuronal
development, Fas appears to regulate neuronal branching in hippocampal
neurons (Zuliani et al., 2006). Additionally, human brain endothelial cells are
resistant to FasL-mediated death, and triggering Fas induces release of matrix
metalloproteinase 9 (Wosik et al., 2007). Thus it appears that the consequence
of Fas activation is varied and cell type specific. Although Fas is a ubiquitous
receptor found on cells throughout the body, its specific role in various cell types
is not known.

We investigated the effects on murine NPC survival, proliferation, and
differentiation in vitro during Fas activation by its cognant ligand (FasL). Our
results indicate that cells grown in minimal medium cell culture (deprived of
growth factors) have an increased cell survival following Fas activation. This
apparent neuroprotection arises from decreased apoptosis as opposed to
augmented cellular proliferation. Furthermore, we found this effect is not as a
result of altered FLIP expression or alterations of the caspase pathway. Rather,
our data show the upregulation of mRNA levels and protein expression of Birc3,
a largely undescribed member of the IAP family of proteins, thus providing a
molecular mechanism for the protective effect of FasL.
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Methods
Isolation of Murine NPCs
Mouse NPCs were obtained from Dr. Jeffrey Spees, University of Vermont Stem
Cell Core. NPCs were isolated from whole brains of individual 4-day post-natal
C57/BL6 mice using NeuroCult® Enzymatic Dissociation Kit (Stem Cell
Technologies). NPCs were identified based on neurosphere formation then
enzymatically dissociated before culturing in a single-cell monolayer.

In the same manner, NPCs were isolated from lpr (Fas-deficient) mouse pups for
specificity experiments. Lpr mice have a retroviral insertion of poly(A) adenylation
signal repeats in the gene for Fas (Nagata & Golstein, 1995). This large insertion
results in improper splicing and truncation of Fas mRNA so that the cells are
devoid of protein expression.

Cell Culture
The undifferentiated murine neural progenitor cells and neurospheres were
cultured in Nunclon delta-coated 75cm2 filter flasks (Nunc) in mouse NPC
complete medium: [1x Neurobasal-A (Invitrogen), 1x B27 supplement
(Invitrogen), 20 ng/ml EGF (BDbiosciences), 10 ng/ml basic FGF (Peprotech), 2
mM L-glutamine (Mediatech Inc.), 100 units/ml penicillin, and 100 µg/ml
streptomycin (Mediatech Inc.)].

55

Statistical Analysis
One way ANOVA was performed to determine statistical significance of the data,
followed by Tukey’s test to compare individual samples. Analyses were run using
Prism 5 (Graph Pad) software.
FasL Treatment
To assess the effect of FasL on NPCs, the cells within four to five passages were
cultured in poly-D-lysine and laminin coated plates. Upon reaching 80-90%
confluency (approximately 3 days), EGF and bFGF were withdrawn, cells were
rinsed, and the cells were treated with recombinant FasL (Alexis Biochemicals)
along with an enhancer (anti-flag M2 monoclonal antibody – Sigma) in minimal
media [1x Neurobasal-A (Invitrogen), 1x B27 supplement (Invitrogen), 2 mM Lglutamine (Mediatech Inc.), 100 units/ml penicillin, and 100 µg/ml streptomycin
(Mediatech Inc.)]. Concentration of FasL was 200 ng/mL for all experiments,
except for the 700 ng/mL Calcein AM experiments. Similarly, an enhancer (antiFlag, Invitrogen) used at the concentration of 4 µg/mL except for the higher
concentration Calcien AM experiment, where 14 µg/mL was used. Some
treatments were done in complete medium (as described in results).
Flow Cytometry
NPCs left in suspension of complete medium in a 5 mL Falcon® tube (12X75
mm) for 2-3 hours before pelleting, rinsing, and FasL addition. FasL treatment
was performed in the presence, or absence of growth factors (i.e. in complete
media or minimal media, respectively). Flow cytometric evaluation of apoptotic
and dead cells was performed with Annexin V Alexa Flour 647 Conjugate assay
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and LIVE/DEAD® blue-fluorescent (UV) reactive dye kit, respectively (both
Invitrogen), according to manufacturer instructions. UV LIVE/DEAD dye
permeates into and reacts throughout the volume of cells which have lost their
membrane integrity, thus labeling necrotic cells. Annexin labels phospholipid
phosphatidylserine residues on the exterior surface of apoptotic cells
(translocation of PS is one of the earliest indicators of apoptosis). Flow
cytometry analysis was performed by a BD LSRII flow cytometer equipped with
3 lasers (488, helium neon, and UV) and data were analyzed with Flow Jo
software.
Cell Viability Assay
Calcein AM (acetomethoxy derivate of calcein) assay is a commonly used
method to meausure cell viability. Calcein AM enters living cells and is
hydrolyzed by intracellular esterases to produce calcein, a strongly fluorescent
compound that remains in the cytoplasm. Calcein AM was added directly to cells
24 and 48 hours post treatment. Murine NPCs were cultured in 48-well plates
and FasL treatments perfomed in minimal media were compared to untreated,
minimal media controls. Both FasL and minimal media control NPCs were
treated with 2 μg/mL Calcein AM (1 mg/mL stock diluted 1:500) and incubated at
37C, 5% CO2, for approximately 30 minutes. Viability measurements were
completed using Fluostar Galaxy spectrophotometry software. The data are
described as relative absorbance (n=8 per condition).
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Mouse NPC BrdU Proliferation Assay
Cell proliferation in the presence

of

FasL

was

characterized

by

bromodeoxyuridine assay. Upon reaching approximately 80% confluency
mNPCs were pulsed for 90 minutes with 100 M bromodeoxyuridine (a thymidine
analog used during DNA synthesis) and fixed with 4% paraformaldehyde and
picric acid (Zamboni’s). DNA was denatured using 2 M HCl and blocked (10%
Horse serum, 0.2% Azide). The primary antibody mouse anti-BrdU IgG (Roche)
was applied (1:100) and allowed to react overnight. A Cy3 anti-mouse secondary
antibody (1:500) was applied and reacted for three hours. Cell counts were
conducted by selecting random fields at a power of 20X and counted by hand.
Total cell count was compared against BrdU positive cell nuclei to characterize
mNPC proliferation. Percentage of positive cells was extrapolated using
Neurolucida Stereoinvestigator Software (n=6 per condition).

TUNEL Assay
Terminal transferase dUTP nick end labeling (TUNEL) assay was performed to
assess cell death from apoptotic signal cascades. Biotinylated dUTP (Roche)
was incorporated into late stage apoptotic DNA using terminal deoxynucleotidyl
transferase (Promega). Cells were stained with streptavidin fluorescein
isothiocyanate (1:1000; Jackson Immunoresearch), a biotin ligand. Cell nuclei
were labeled with Hoechst dye (1:2000) and visualized with UV microscopy. Cell
counts were conducted by selecting random fields at a magnification of 20X and
counted by hand comparing total Hoechst signal (491 nm) versus apoptotic
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nuclei positive for Strep-FITC (515-565 nm). The percentage of positive cells was
extrapolated using Neurolucida Stereoinvestigator Software (n=4 per condition).

RT-qPCR
Total RNA was isolated from both triplicate FasL-treated and minimal media
controls using RNeasy Mini Kit (Qiagen). cDNA was amplified using Superscript
IIITM First-Strand Synthesis Supermix for qRT-PCR (Invitrogen). NPC RNA was
quantified by Nanodrop and synthesis of cDNA was completed using
Superscript III First-Strand Synthesis Supermix (Invitrogen). mNPC cell fate and
FasL expression analysis was completed using Applied Biosystems 7500 Fast
Software

real

time-quantitative

polymerase

chain

reaction

(RT-qPCR).

Amplification consisted of 50 cycles (95C for 15 seconds and 60C for 1 minute)
with approximately 15 ng/L cDNA, specific primer pairs for β-tubulin III,
PDGFRα, GFAP, and GLAST; and TaqMan Master Mix (all Applied Biosystems).
Neuron (β-tubulin III), astrocyte (GFAP and GLAST), and oligodendrocyte
(PDGFRα) mRNA transcript expressions were analyzed. Cycle threshold
amplifications for mNPC cDNA were normalized against endogenous control
marker Actin and subsequently expressed as fold differences relative to lineage
marker and treatment condition. The 2-∆∆Ct method was used to calculate the
relative expression of genes. Same methods were used with Birc3/c-IAP2 primer
(also from Applied Biosystems, Assay on Demand). For each primer, the
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experiment was replicated 3 times (n=3). RT-qPCR experiments were replicated
6 times (n=6)
Immunocytochemistry
Cells were plated on coated (poly-D and laminin) coverslips in 12-well plates.
After the treatment period, cells/coverlips were fixed Zamboni’s Fixative (4%
paraformaldehyde; 15% picric acid). Cells were incubated overnight at 4οC in the
following anti-mouse antibodies: nestin (Novus Biologicals, 1:250), β-tubulin III
(AbCam, 1:100) GFAP (Eucor Biotech, 1:500), and NG2 (R&D, 1:500). The
nestin antisera was made in chicken, all the rest were made in rabbit. After
rinsing twice in phosphate buffered saline, cells were incubated for 2 hours at
room temperature in both anti-chicken Cy2 (1:250) and anti-rabbit Cy3 (1:500)
secondary antibodies (both Jackson Immunoresearch)
Western Blot Analyses
For Western blot analyses, the mNPC cultures were lysed in 2X lysis buffer with
0.5% NP-40 (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2mM sodium
orthovanidate, 10% glycerol, and 1 tablet/25mL “Complete” protease inhibitor
[Roche Diagnostics]) SDS). The proteins (32 μg) were fractionated on 4 - 12%
SDS-PAGE gels and transferred onto Immobilon-P PVDF membranes (Millipore)
for Western analyses using primary antibodies to FLIP (ProSci Incorporated),
caspase-8 (Apotech), caspase-3 (not commercially avalible, gift from Dr. Ralph
Budd), β-tubulin III (Sigma), GFAP (Applied Biological Material), myelin
oligodendrocyte glycoprotein (MOG, R & D Systems), and actin (Santa Cruz); the
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blots were stripped in 62.5 mM Tris-HCl, pH 6.7, containing 2% SDS and 100
mM β-mercaptoethanol at 50 oC for 90 min before each reprobing procedure.
Horseradish peroxidase-conjugated secondary antibodies were used. The blots
were

processed for enhanced

electrochemiluminescence

detection

(GE

Healthcare); all blots were exposed to autoradiographic film for signal detection.
Two separate Western blot experiments were performed for the FLIP/caspase8/caspase-3 probing. Blots using c-IAP2/Birc3 (Santa Cruz) as a primary
antibody were processed similarly except secondary antibody (goat anti-rabbit
alexa fluor 680-conjugated: Molecular probes) was incubated in Odyssey Buffer
and signal detection was performed using Odyssey 2.0 infrared imaging system.
Birc3 western blot experiment was replicated three times (n=3).

Results

Murine NPCs express Fas and FasL
To confirm the presence of Fas on murine NPCs, both surface receptor and
mRNA expression were investigated. Surface receptor expression was confirmed
using flow cytometry. Mouse CD4+ cells were used as a positive control because
T-cells are known to be high expressors of Fas. mNPCs and T-cells were stained
with a Fas-specific antibody conjugated to PE. Intensity of fluorescence revealed
mNPCs are positive for Fas, and levels are comparable to that which is seen in
T-cells (see Figure 1).
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Expression of FasL in mNPC minimal and complete media cultures and
unstimulated mouse CD4+ T-cells was determined using RT-qPCR. Ct values
(from both mouse apoptosis Superarray plate analysis and RT-qPCR) indicated
low levels of FasL mRNA expression in NPCs grown in minimal and complete
media (average Ct values of 38.2 and 36.8, respectively). These expression
levels are very low compared to average T-cell expression levels (average Ct
value = 27.7). These data indicate that adult NPCs express high levels of the Fas
receptor, but minimal amounts of FasL in primary culture.

FasL induces cell death in T-cells but not NPCs
To elucidate the physiological role of Fas/FasL in adult NPCs, we tested the
ability of recombinant FasL to induce cell death. Induction of apoptosis and
quantity of dead cells was assessed at two time points (3 hrs and 15 hrs) using
UV Live/Dead Dye and Annexin staining. UV Live/Dead dye permeates into and
reacts throughout the volume of cells which have lost their membrane integrity,
thus labeling necrotic cells. Annexin labels phospholipid phosphatidylserine
residues on the exterior surface of apoptotic cells (translocation of PS is one of
the earliest indicators of apoptosis). Mouse T-cells (isolated from lymph nodes of
wild-type C57/BL6 mice) were used as a positive control because they are known
to be sensitive to FasL induced cell death. At both 3 hr and 15 hr time points, a
substantial amount of FasL induced cell death was observed in the T-cells when
compared to untreated controls. There was a 4-fold increase in the percentage of
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dead and dying T-cells at 3 hrs with FasL treatment, while FasL treatment
increased the percentage of dead and dying T-cells from 34.2% to 85.8% at the
15 hr time point (Figure 2a, top row). Similar results were obtained when using
human Jurkat T-cells (data not shown).

We did not observe any FasL-induced cell death in the NPCs at the early or late
time point in either complete or minimal media (middle and last rows of Figure
2a). Interestingly, for cells incubated in minimal media, we observed a decreased
percentage of dead and dying cells in the FasL treated NPC at 15hrs (Figure 2b,
bottom panels). 80% of control NPCs stained positive for UV Live/Dead and/or
Annexin dyes while only 62% of FasL-treated cells were positive. Therefore, it
appeared FasL may exhibit a protective effect against apoptosis.

FasL increases NPC survival upon growth factor withdrawal
When NPCs are deprived of epidermal growth factor and fibroblast growth factor
(i.e. when cells are placed in minimal medium), a large number of cells die (Kuhn
et al., 1997; Slinskey et al., 1999). In order to determine if FasL exposure
increased cell survival under growth factor deprivation conditions, we assessed
cell viability using Calcein AM assay. FasL treated NPCs were compared to
control NPCs at 24 and 48 hours. No change was observed in treated (at either
200 ng/mL or 700 ng/mL concentrations) versus control at 24hrs (Figure 3a).
However, at 48 hours (see Figure 3b) there was a dose-dependent response,
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with FasL-treated cells having increased survival. These results are consistent
with the flow cytometry data discussed above. Therefore two different methods of
assessing cell viability demonstrate more NPCs survive under conditions of
growth factor starvation when Fas is activated.

Decreased murine NPC apoptosis with FasL treatment
The results from annexin/UV live-dead dye and Calcein AM assays prompted us
to investigate whether the protective effects of FasL in NPCs were due to a
decrease in apoptosis, an increase in proliferation, or both. Results from the
TUNEL assay showed a trend in the direction of decreased apoptosis for FasL
treated cells at 24hrs (see Figure 3c), although this did not differ significantly
from untreated controls. However, FasL-treated cells had a significantly lower
percentage of apoptotic cells (see Figure 3d) after 48 hours lacking growth
factors.

FasL does not influence NPC proliferation or differentiation
To assess whether FasL possesses proliferative properties in NPC, a series of
BrdU-labeling studies was performed. In EGF- and FGF-supplemented medium,
more than 75% of NPCs were labeled with BrdU, demonstrating the high
proliferative state of the cells under optimal culture conditions. Growth factor
withdrawal diminished NPC proliferation precipitously to less than 7% of the
population. FasL-treated cells showed a similar percentage of BrdU+ cells
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(Figure 4a). Therefore, these data show that the increase in viability of NPCs
following Fas activation is the result of decreased apoptosis.

In addition to attenuating apoptosis in NPCs, Fas could play a role in
differentiation. Effects of FasL exposure on mNPC differentiation were assessed
using both RT-qPCR and immunocytochemistry. RT-qPCR revealed that the
mRNA expression levels of GFAP and GLAST (astrocyte markers), β-tubulin III
(neuron marker), and PDGFR-α (oligodendrocyte marker) were not significantly
different when comparing FasL treated NPCs to control NPCs in minimal media
(Figure 4b). Control cells were used as the calibrator sample and normalized to
β-actin. Thus, Fas activation does not facilitate differentiation into astrocytes,
neurons, or oligodendrocytes. The RT-qPCR data are consistent with
immunocytochemistry results (Figure 4c).

FasL treatment does not affect the levels of FLIP, caspase-8, or caspase-3 in
NPCs
In light of our data supporting decreased apoptosis after Fas activation, we
sought to investigate the intracellular pathways that may be responsible for this
effect. Fas mediates cell death by way of the extrinsic pathway, whereas
activation of the receptor causes receptors to oligomerize - subsequently
inducing the formation of DISC (death-inducing signaling complex), which
includes FADD (Fas associated death domain) and caspase-8 (Wajant, 2002).
Proteolytic activity of the DISC complex results in the activation of caspase-8,
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which consequently activates (either directly or indirectly, depending on the type
of cell) caspase-3, the effector caspase (Wajant, 2002). FLIP, an inhibitor of Fas
mediated cell death, acts by inhibiting the activation of caspase-8 (Nagata &
Golstein, 1995). It is known that high levels of FLIP expression correlate with
resistance to Fas-mediated cell death, while decreased expression of FLIP
renders cells sensitive to apoptosis (Tschopp et al., 1998). Thus, we investigated
whether altered FLIP expression could account for the anti-apoptotic effects of
Fas activation we observed. Western blot revealed an increase in the p43 DISCassociated cleavage form [FLIP(p43)], with a consequent decrease in the full
length form in T-cell controls treated with FasL (Figure 5b) This pattern was not
seen in treated NPCs, however, and there was no change in the FLIP expression
pattern upon Fas activation. Thus, FLIP upregulation cannot explain the
protective effects against apoptosis observed with Fas activation in NPC.

Furthermore, we were interested in caspase-8 and caspase-3 protein expression,
which are indicators of up- and down-stream stages of caspase mediated
apoptosis, respectively. Levels of both caspase-3 and caspase-8 remain steady
in T-cells (Figure 5c & 5d). This is likely due to active FLIP inhibiting the
activation of caspase-8 (Tschopp et al. 1998). There was no difference in the
expression of caspase-8 in FasL treated NPCs versus controls (Figure 5c).
Furthermore, we found no change in pro-caspase-3 levels and no detectable
induction of cleavage into the active form (see Figure 5a). Consequently, our
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findings showed that the protective effects against apoptosis resulting from Fas
activation are not the result of FLIP upregulation, nor the inhibition of caspase-8
or caspase-3 activity in the extrinsic cell death pathway. Additionally, our
Western results on the levels of these caspases were consistent with our initial
experiments that show no induction of cell death.

The anti-apoptotic gene Birc3 is responsible for FasL anti-apoptotic effects
The novel finding of increased cell survival, without involvement of FLIP, led us to
search for possible genes that could be involved in this process. We used a
mouse apoptosis PCR micro-array to (SuperArray) screen for genes involved in
FasL anti-apoptotic effects on NPC. We found that the IAP Birc3 (also known as
cIAP-2) was upregulated by a factor of 7.19 (p<0.000001) in FasL treated cells
compared with controls (averaged from 3 samples each of FasL-treated and nontreated NPCs in minimal media). Birc3 mRNA upregulation appeared to be
specific, as other anti-apoptotic genes were not affected by FasL treatment
(Table 1). This finding was confirmed using Applied Biosystems assay on
demand primer for Birc3/c-IAP2 (Ref Seq #: NM_007464.3; Assay ID:
Mm00431800_m1). Results showed an increased Birc3 mRNA expression of
approximately 7.63 fold (SD= +/-1.53, n=4) in FasL-treated cells compared with
controls (Figure 6a). Western blot analysis was consistent with the mRNA data,
showing a statistically significant increase in Birc3 protein expression in the
FasL-treated sample (Figure 6b). Birc3 is one of several genes in the IAP family
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that were originally identified in baculoviruses where they inhibited infected cells
from death (Schimmer, 2004).
FasL effects on NPCs are specific
It is possible that the observed effects on NPC could work through some Fasindependent/non-specific mechanism. In order to explore this possibility, we
compared the effects of FasL on wild type and Fas-deficient (lpr) NPCs. Both lpr
and wild-type NPCs were treated with FasL or control (minimal media) for 48hrs,
as in previous experiments. Afterwards, RNA was extracted and the expression
level of Birc3 mRNA was analyzed using RT-qPCR. In contrast to wild-type
NPCs, there was no difference in apoptosis for FasL and control lpr samples
(Figure 7). This is indicative of a specific interaction between FasL and its
cognant receptor that leads to a decrease in apoptosis.

Discussion
We investigated the effects of FasL/Fas on neural progenitor cell survival,
proliferation, and differentiation in vitro. NPCs express high levels of FasR, and
relatively low levels of FasL.

Our data show that under optimal conditions (complete media with growth
factors), Fas activation via FasL in NPCs does not induce apoptosis. This is in
contrast to T-cell controls (known to be highly sensitive to Fas-induced cell
death), which demonstrated a significant amount of cell death following Fas
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activation. In the absence of growth factors (under minimal medium conditions),
FasL promoted NPC survival and abrogated the apoptosis response. Our
findings are in line with results of other studies with adult NPCs (Ceccatelli et al.,
2004), neuronally differentiatied precursor cells (Brunlid et al., 2007), and a
neural stem cell line (Tamm et al., 2004), all of which also find no induction of
apoptosis after Fas activation using various methodologies. Although insensitivity
to Fas-induced cell death in NPCs has been previously reported (Brunlid et al.,
2007; Ceccatelli et al., 2004), ours is the first and only study that suggests a
protective effect of Fas activation against apoptosis.

To our knowledge, this is the first study that begins to provide a detailed
characterization of the intracellular pathways involved in Fas activation. Our
results show that FLIP, an inhibitor of caspase-8 mediated cell death, is not
involved in the inhibition of apoptosis. In addition, we found no activation of
caspase-8 or caspase-3, further supporting findings of the lack of apoptosis
induction with Fas activation in NPCs. It is possible that caspase-8 levels in NPC
are not sufficient to initiate the apoptosis cascade (Ricci-Vitiani et al., 2004).
Interested to find what other genes could be involved in this process, we
discovered Birc3, an IAP, is up-regulated following Fas activation providing a
probable mechanism for the anti-apoptotic effects of FasL on NPCs.
Furthermore, presence of Fas is required for observed anti-apototic effects to
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occur. Therefore, FasL does not work through a non-specific mechanism or
alternate pathway.

The identification of factors capable of maintaining CNS NPC populations is
important in a variety of contexts. Developmentally, the rates of NPC apoptosis
and differentiation are determinants that define neuronal populations and
cytoarchitecture.

In adults, continuous NPC renewal has been implicated in

learning and memory, maintaining olfactory function, mediating therapeutics for
behavioral or psychiatric disorders, and providing an endogenous means of
neuronal repair after injury (Gould et al., 1999; Okano et al., 2007; Sahay & Hen,
2007; Sohur et al., 2006). If accumulating cellular insults, or changes in
environmental niches result in decreased NPC regenerative capacity to repair
CNS damage from degenerative diseases or injury, then diminished NPC
apoptosis may be an important contributor to the constellation of neurological
defects associated with CNS repair.

Several growth factors and cytokines,

including EGF, bFGF, vascular endothelial growth factor (VEGF), brain derived
nerve growth factor (BDNF), prolactin, leukemia inhibitory factor (LIF) and ciliary
neurotrophic factor (CNTF) have been shown to be capable of promoting stem
cell renewal; the addition of FasL to the repertoire not only presents alternatives,
but also options for coordinate treatments to amplify and refine NPC survival.
Although the role of Fas for immunoregulatory cells is fairly well characterized,
the role of Fas in neural stem cell physiology is not clear.
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Our results suggest a novel role for a member of the IAP family, Birc3, in
promoting neural stem cell survival following activation of the Fas/FasL pathway.
IAPs are a family of anti-apoptotic proteins that specifically inhibit caspase-3, -8,
and 9 (Schimmer, 2004). A total of 8 proteins have been identified in humans
thus far, based on both presence of BIR (baculovirus IAP repeat) domain and
anti-apoptotic activity (Schimmer, 2004). Little is known about the functions of
IAPs, particularly c-IAP2/Birc3, in the nervous system. Different members of the
IAP family have been investigated for involvement in various neurological
diseases. For example, neuronal apoptosis inhibitor protein (NAIP) is
upregulated in rat neurons in response to transient forebrain ischemia (Xu et al.,
1997). At molecular level, IAP-1 and -3 are down-regulated in microglia following
treatment with transforming growth factor (TGF)-β, thus indicating a role for IAPs
in mediating CNS inflammatory response (Jung et al., 2003). Knowledge of these
mechanisms could be translated to therapeutic technologies for diseases like
MS. Furthermore, increased IAP expression in the T-cells of MS patients
correlates with disease activity, while interferon-beta therapy decreases IAP
expression in these cells (Semra et al., 2002; Sharief et al., 2002). This
implicates IAP expression as an important regulator of T-cell survival in, and thus
pathology of MS. The full involvement of IAPs and the specific pathways they
affect remain to be elucidated in both healthy neuronal cells and in disease
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states. Further elucidation of this and other pathways regulating the apoptosis of
NPCs are required before their full therapeutic potential can be obtained.

It is possible that the role of Fas changes depending on the developmental stage
and proliferative properties of the stem cells. Different from our observations,
Fas monoclonal antibody Jo2-induced apoptosis of wild type embryonic stem
cells (ESCs) isolated from 15 day-old mouse but not the ESCs from Fas-/-(lpr)
mice (Semont et al., 2004). A recent study on human ESCs found Fas, FasL,
caspase-8, and caspase-3 are all up-regulated after exposure to the toxic
environmental contaminants nonylphenol and octylphenol (Kim et al., 2006). It is
unclear whether the Fas up-regulation in response to toxins in this study had a
net protective or death-inducing effect. These results appear contrary to our work
and other work with adult NPCs (Ceccatelli et al., 2004), neuronally differentiated
progenitor cells (Brunlid et al., 2007) and a neural stem cell line (Tamm et al.,
2004), all of which demonstrate that Fas-dependent apoptosis pathway is not
functional in these cells. Although the reasons of these differences are unclear,
they may be related to the original source of the neural stem cells, culture
maintenance and treatment conditions. Taken together, our findings and others
suggest an important role of Fas in regulating developmental neuronal death.
Fas may play an evolving, pluripotency dependent role in maintenance of the
CNS.
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Neural stem cell transplantation therapies are a promising investigative avenue
for several neurodegenerative diseases. According to Pluchino’s findings, NPC
transplantation results in a therapeutic effect for EAE mice, the widely used
animal model of human CNS demyelinating diseases (Pluchino & Martino, 2005).
It is thought that this observed effect could be mediated by a “bystander” process
in which transplanted neural stem cells are able to inhibit destructive T-cells and
promote the growth and survival of existing neurons by releasing neuroprotective
molecules (Martino & Pluchino, 2006; Pluchino & Martino, 2008). This is in
contrast to the “cell replacement” hypothesis, where transplanted neural
progenitor cells repopulate a damaged CNS. In order to be able to harness the
full therapeutic potential of neural stem cells, characterization of the biochemical
mechanisms that regulate their survival is essential. Our study shows that the
FasL/Fas pathway does not induce cell death in murine progenitor cells, and that
FasL increases the survival of NPCs by decreasing apoptosis; Birc3 is a
probable candidate for modulating this process, though further studies are
required before a definitive statement can be made. Modulating this pathway
may impact NPC survival and cell fate commitment, which may be important for
NPC in vitro expansion and then in vivo therapeutic applications.

Conclusion
We investigated the effects of FasL/Fas on neural progenitor cell (NPC) survival,
proliferation, and differentiation in vitro. We have found that FasL increases NPC
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survival upon withdrawal from growth factors, without affecting cell differentiation
properties. This increased cell viability appears to be the result of decreased
apoptosis, rather than an increase in proliferation. The apparent protective effect
against apoptosis induced by FasL is not a result of increased FLIP, a molecule
known to inhibit caspase-8 mediated cell death in T-cells. However, a possible
mechanism could be through Birc3, a member of the inhibitor of apoptosis family
of proteins, that was found to be upregulated in cells treated with FasL. These
effects were negated in Fas-deficient NPC, confirming the specificity of this
interaction. Therefore, we describe a novel pathway for NPC survival involving
the Fas system and Birc3.
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Table 2-1: FasL effects on anti-apoptotic gene expression
Table lists results from mouse apoptosis gene array analysis. RNA was extracted
from NPC control and FasL (200 ng/mL) treated cells grown in minimal medium
for 48 hrs. Of all the anti-apoptotic genes tested, the Birc3 was the only one that
showed a significant change in mRNA expression with FasL treatement. Fold
differences and p values obtained from averaging 3 separate arrays (n=3).
Positive numbers indicate up-regulation while negative numbers indicate downregulation. Fold difference obtained by following equation: (2 -ΔCt FasL)/(2-ΔCt
Control).
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Anti-Apoptosis
Gene
Akt1
Api5
Ataf5
Bag1
Bag3
Bcl2
Bcl2l1
Bcl2l2
Birc1a
Birc1b
Birc2
Birc3
Birc4
Birc5
Bnip3
Casp2
Cflar
Dad1
Tsc22d3
Hells
ll10
Lhx4
Mcl1
Nfkb1
Nme5
Pak7
Pim2
Polb
Prdx2
Rnf7
Sphk2
Tnf
Cd40lg
Zc3hc

Fold Up- or DownRegulation
(FasL NPC/Control NPC)
1.07
1.05
-1.19
-1.15
-1.00
1.27
-1.15
-1.08
1.15
1.07
1.07
7.19*
1.14
1.03
1.05
1.25
1.49
2.06**
1.01
1.52
1.69
-1.29
-1.02
1.02
1.09
1.21
1.19
1.20
-1.15
-1.20
1.01
-1.03
1.08
1.12

*p value <0.00001
**p value > 0.05
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Figure 2-1: NPCs express significant amounts of FasR
PE conjugated monoclonal antibody to FasR detected using flow cytometry.
Fluorescence represents % of maximum intensity, thus some cells have higher
density of the receptor than others. Cells were stained with PE-conjugated FasR
Ab for 30 min after blocking with isotype control antibody. PE fluorescence (blue
line) is overlayed with baseline fluorescence (red) – obtained from cells were only
blocked with isotype control
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Figure 2-2: FasL does not induce cell death in NPCs

T-cells and NPCs were treated with FasL (200 ng/mL) plus an enhancer
(4 ug/mL) for 3 and 15 hrs at 37C before staining. All cells were stained with UV
Blue Live/Dead dye and Annexin alexa-fluor 647. Cells were subsequently
scanned using flow cytometry. For a-l, lower left quadrant (I) represents cells
living healthy cells which stain negative for either dye; the lower right quadrant
(II) represents early apoptotic cells which are positive for annexin; the upper right
quadrant (III) represents dead and dying cells which stain positive for both
annexin and UV Live dead dye; the upper left quadrant (IV) includes only necrotic
cells (i.e. positive for only UV/Live dead dye). For T-cells growing in optimal
culture conditions (complete RPMI supplemented with IL-2), death was induced
after 3 hrs of FasL treatment, as evidence by the approximate 4-fold increase in
the percentage of apoptotic cells (i.e. annexin positive) in treated (b) versus
untreated (a) samples. A dramatic increase in the amount of apoptotic and
necrotic cells was observed in TCs treated with FasL for 15 hrs (d) compared to
controls (c). No effect on NPCs was observed after 3 or 15 hrs of FasL treatment
in complete neurobasal medium supplemented with EGF and FGF (e-h). No
induction of death was observed in NPCs treated for 3 hrs with FasL in minimal
medium (e) compared to control cells (f). A slight decrease (approximately 18%)
in the total dead and dying cells was observed in NPCs treated with FasL for 15
hrs (h) compared to controls (g).
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Figure 2-3: Fas Activation promotes NPC survival by decreasing apoptosis
Calciein AM (acetomethoxy derivate of calcein) assay is a commonly used
method to meausure cell viability. Calcein AM enters living cells and is
hydrolyzed by intracellular esterases to produce calcein, a strongly fluorescent
compound that remains in the cytoplasm. In a-b fluorescence was measured
using Fluostar Galaxy spectrophotometry software and the Y-axis (absorbance)
is in arbitrary units and is equivalent to cell viability. (a) Calcien AM assay
revealed no change in cell viability after 24 hrs in minimal media at two different
concentrations of FasL. (b) At 48 hrs, there was a dose-dependent increase in
cell viability for treated NPCs. The difference was statistically significant at 700
ng/mL (p<0.05, n=8) using ANOVA. Y-axis (absorbance) is equivalent to cell
viability. (c) and (d) show results from TUNEL (terminal deoxynucleotidyl
transferase Biotin-dUTP nick end labeling) assay experiments, which allows for
quantification of apoptotic cells by labeling broken strands of DNA. Cells treated
with FasL (200 ng/mL) in minimal medium are compared to control cells grown in
minimal medium. Healthy NPCs grown complete medium (includes EGF and
FGF growth factors) provide a negative control (leftmost column). (c) At 24 hrs
following growth factor removal, there is a trend toward decreased percentage of
apoptosis in NPCs treated with FasL. (d) A significantly decreased amount of
apoptosis (p<0.01, n=4) was observed in NPCs treated with FasL treatment for
48 hrs in the absence of growth factor.
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Figure 2-4: Fas Activation does not influence NPC differentiation or
proliferation
(a) Cells treated with 200 ng/mL FasL were fixed and proliferation was
subsequently assesed using BrDU-assay. No significant difference was detected
between FasL treated cells and controls (minimal media). Results include
proliferation of cells in complete media (with growth factors) for comparison. % of
BrDU positive cells was determined by comparing with total number of cells
(stained with Hoescht nuclear dye). Random fields were counted at 20X using
Neurolucida Steroinvestigator Software. n=4 (# of slides per condition). (b) RNA
extracted from NPC treated for 72 hrs with FasL in minimal media was subjected
to cDNA reverse transcription, and the resulting cDNA was analyzed using RTqPCR. NPC cDNA were normalized against β-Actin (endogenous control marker)
and subsequently expressed as fold differences relative to NPC grown in minimal
media. Specific primer pairs for β-TubulinIII, platelet-derived growth factor
receptor (PDGFR)-α, glial fibrillary acidic protein (GFAP), and astrocyte-specific
glutamate transporter (GLAST) were utilized to determine mRNA expression.
The 2-ΔΔCt method was used to calculate the relative expression of genes. FasL
treatment had no effect on oligodendrocyte (PDGFRα), neuronal (betaTubulinIII), or astrocyte GLAST & GFAP) lineage differentation. Data represent
the mean from 5 different cultures ±SEM (n=4, p>0.05). (c) Cells were grown to
confluency on poly-D and laminin coated coverslips. Spontaneous differentiation,
upon withdrawal of growth factors for 48 hrs (top panels) was compared to 48 hr
FasL treated cells (bottom panels). Cells were fixed with Zamboni’s fixative and
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then co-stained with anti-mouse nestin (chicken) and NG2, B-TubulinIII, or GFAP
(all rabbit anti-mouse) primary antibodies. All coverslips were then stained with
both anti-chicken Cy2 and anti-rabbit Cy3 secondary antibodies. Mounted slides
were visualized using Nikon Eclipse E800 flourescent microscope and photos
were taken using Photometrics CoolSNAPTM cf software. No significant
difference in any lineage marker was observed upon FasL treatment (n=3).
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Figure 2-5: FasL does not influence FLIP or caspase levels in NPCs
Western blot results for probing the signaling cascades involved in Fas
activation. Cell lysates obtained using NP-40 after various treatment periods of
200 ng/mL FasL + 4 ug/mL α-flag (enhancer). Blot was first probed using an antiFLIP antibody; then the blot was consecutively stripped and re-probed for
caspase-8, caspase-3, and finally β-actin. Secondary antibodies were HRPconjugated, and visualized using ECL development reagents. FLIP levels remain
unchanged in NPCs after FasL Treatment; NPCs express low levels of caspase8, and expression is not changed with FasL treatment at various time points; the
levels of procaspase-3 (~29 kDa) remains unchanged; In contrast to T-cells the
activated (cleaved) form of caspase-3 (~16 kDa) is not produced in NPCs after
FasL treatment at various time points.
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Figure 2-6: Birc3 upregulation correlates with Fas activation
(a) RT-qPCR results showing mRNA expression of Birc3 is upregulated in FasL
treated cells compared to controls after growing for 48 hrs in minimal medium.
Control cells were used as calibrator sample and results normalized to β-actin
mRNA expression. (b) Birc3 protein expression is significantly upregulated in
NPCs treated with FasL. Cell lysates collected from control and FasL cells grown
in minimal medium for 48 hrs. Top: Western blot probed with rabbit α-Birc3/cIAP2 antibody and then incubated with an α-rabbit secondary antibody conjugated to
alexa Fluor 680. Positive band for Birc3 (~68 kDa) was visualized using
Odyssey® infrared imaging system. Bottom: semi-quantitation of bands using
densiometric analysis (n=3, p<0.05 using Students t-test); protein levels were
normalized to beta-actin.
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Figure 2-7: Induction of Birc3 expression is dependent on Fas expression
RT-qPCR results comparing Birc3 mRNA expression in FasL treated wild-type
(wt) versus lpr (Fas-deficient) NPCs. Statistically significant Birc3 upregulation
was observed in wt (p<0.01, n=3), but not lpr NPCs. Both wt and lpr NPCs were
isolated from 4-day postnatal BL6/C57 mouse pups according to manufacturer
instructions using NeuroCult® Kit for CNS tissues. Cells were grown into free
floating neurospheres in complete medium before consequently dissociating into
single cells an plating in a monolayer. These monolayer cells were grown to
80% confluency and treated with FasL for 48 hrs before RNA extraction.
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Abstract
Although transplanted neural stem/progenitor cells (NPCs) can ameliorate
disease course in animal models of central nervous system inflammatory and
neurodegenerative diseases, little is known about the regulation of NPC
differentiation and proliferation. The Fas receptor, a member of the tumor
necrosis factor (TNF) superfamily, has recently been shown to be important in
NPC survival and immunoregulatory functions. We were interested in further
investigating this system utilizing NPCs isolated from Fas-deficient (lpr) mutant
mice.

We found that lpr NPCs have increased survival and decreased proliferation.
Additionally, RT-qPCR, confocal microscopy, and flow cytometry surface staining
reveal that lpr NPCs have a significantly more robust differentiation to neuronal
and oligoprogenitor cell lineages as compared to wild-type (wt) NPCs. These
effects correlated with an upregulation of three of the major fate specification
modulators in lpr NPCs: sonic hedgehog (Shh), slit homolog 2 (Slit2), and
noggin.

These data indicate Fas plays an important role in determining the stemness and
differentiation fate of NPCs. Additionally, our research reveals a novel connection
between Fas and major modulators of NPC differentiation – Shh, Noggin, and
Slit2. This is the first indication of a possible link between Fas and these
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particular signaling molecules that control neuronal fate specification. Therefore,
our results suggest Fas is a novel target for controlling the development of
neurons versus mature oligodendrocytes.

Introduction
There is a critical need for developing direct neuroregenerative therapies for
demyelinating diseases, including Multiple Sclerosis (MS). Currently MS
treatments are limited to peripheral immunoregulation and are ineffective in later,
progressively neurodegenerative stages of the disease. Neural stem/progenitor
cell (NPC) therapies offer a potentially powerful treatment approach for the
chronic neurodegeneration that occurs in these later stages (Pluchino & Martino,
2005). The two main experimental modalities for NPC therapy are exogenous
transplantation and activation/recruitment of the endogenous adult NPC
compartment (Martino & Pluchino, 2006). In either method, differentiation and
integration of NPCs to enhance central nervous system (CNS) repair is the most
sought after outcome. Though exogenous application of NPC has shown
significant recovery in animal models of MS (experimental autoimmune
encephalomyelitis), the functional integration and terminal differentiation of
transplanted cells is extremely rare (Pluchino & Martino, 2005; Pluchino et al.,
2005). The signaling pathways that control NPC survival and differentiation are
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not well understood; therefore, elucidating these complex pathways is paramount
for advancing this therapeutic approach.

The Fas receptor (hereafter referred to as “Fas”) – a member of the TNF receptor
superfamily - has emerged as a major modulator of NPC biology. Previous
knowledge limited this receptor to cell-death related roles: in the immune system
controlling homeostasis by inducing T-cell death (Nagata & Golstein, 1995), and
in the CNS mediating programmed death during embryologic development (Nat,
et al., 2001; van Landeghem, et al., 2002). However, Fas is now recognized as a
mediator of diverse, cell-dependent mechanisms. Namely, activation of Fas via
its cognant ligand (FasL) promotes survival in NPCs (Corsini et al., 2009; Knight
et al., 2009). Furthermore, Fas activation induces neurogenesis and neurite
outgrowth (Corsini et al., 2009). These recent findings suggest that Fas plays a
complex role in mediating NPC fate, and modulation of this pathway may be a
crucial target for future therapies.

In this study, we utilized NPCs isolated from the brains of Fas-deficient (lpr)
mutant mice to further investigate the role of Fas in mediating NPC fate. Here we
report that lpr NPCs exhibit increased survival, increased neuronal specification,
and higher populations of oligoprogenitor cells (OPCs) compared to wild type (wt)
NPCs. Consistent with a more committed progenitor phenotype, lpr NPCs show
deficiency in mitogenic capacity. We have identified the signaling molecules
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sonic hedgehog (Shh), Slit2, Hes1, and Noggin as probable mediators of these
phenomena.

Results
Lpr NPCs do not express Fas
In order to confirm that lpr NPCs lack Fas, we stained NPCs with a Fas-specific
phycoerythrin (PE)-conjugated antibody (or isotype control antibody). Flow
cytometric analysis demonstrates high levels of Fas surface expression in wt
NPCs, and no Fas expression in lpr NPCs (Figure 1).

Fas-deficient NPCs have stunted proliferation and neurosphere formation
Proliferation in response to mitogens and the ability to self-renew are defining
properties of NPCs. All proliferation experiments were performed in the presence
of epidermal growth factor (EGF) and fibroblast growth factor (FGF). A
bromodeoxyuridine (BrDU) assay was used to determine the effects of Fas
deficency on NPC proliferation. Lpr NPCs showed significantly less BrDU
incorporation over 16 hours in complete media compared to wt NPCs. Lpr NPCs
had 18% ±1.6 less proliferation compared to wt (Figure 2a).

Additionally, neurosphere growth in lpr NPCs was abrogated compared to wt
NPCs (Figure 2b). We performed the neurosphere assay to quantify this
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difference. In this assay, size of the neurosphere is an indicator of mitogenic or
proliferative capacity, while neurosphere number is an estimate of the absolute
total number of putative stem cells (Pluchino, et al., 2008). Over three
subsequent passages, lpr NPCs developed significantly smaller neurospheres
than wt (Figure 2c), while the total number of neurospheres remained the same
(Figure 2d).

To be certain the abrogated proliferative capacity of lpr NPCs was not due to
altered apoptosis profiles, we also performed UV Live-Dead dye (labeling dead
cells) and annexin (labeling early apoptotic cells) double-staining on NPCs
growing in the presence of growth factors (EGF and FGF, similar to proliferation
experiments). Four days post-cell plating, there was no difference in the amount
of dead and dying cells in lpr and wt cultures (Figure 2e,f). Quantification of the
data showed no significant difference between the percentage of live/healthy
cells in lpr (97%±2.3) and wt (95%±2.6) cells. Therefore, the decrease in
proliferation cannot be attributed to increased cell death.
In summary, Fas deficient NPCs are deficient in proliferative properties,
evidenced by decreased BrDU incorporation and smaller sphere size, but Fas
expression has no impact on the total number of stem cells (number of
neurospheres).
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Enhanced survival of lpr NPCs in growth factor-free conditions
The ability of NPCs to survive in the absence of growth factors (EGF, FGF) is a
fundamental issue for transplantation models. If NPCs are unable to survive after
transplantation due to inadequate levels of growth factors, their beneficial effects
are negated. Normally, upon growth factor withdrawal in vitro, a large percentage
of NPCs die (Knight, et al., 2009). We observed significantly higher survival in lpr
NPCs (42%) compared to wt NPCs (25%) after 48 hours in minimal media (no
EGF or FGF) using UV/Annexin staining (described above). Therefore, the
percentage of live/healthy cells in lpr cultures after growth factor withdrawal is
nearly doubled when compared to wt NPCs (Figure 3a,b).

Lpr NPCs exhibit enhanced differentiation to neuronal and oligoprogenitor cell
lineages
One distinguishing feature of NPCs is their capacity to differentiate into the three
neuroectodermal lineages. We compared lpr and wt NPC lineage marker RNA
expression for astrocytes (glial fibrillary acidic protein (GFAP), glutamate
aspartate transporter (GLAST)), OPCs (platelet-derived growth factor receptor-α
(PDGFRα) and neurons (βIII-tubulin, Doublecortin (Dcx)) using RT-qPCR. After
two days of differentiation, lpr NPCs expressed significantly higher levels of OPC
and neuronal markers compared to wt NPCs (Figure 4a). This trend maintained
statistical significance after seven days in differentiating media (Figure 4b).
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We confirmed the enhanced OPC phenotype in lpr NPCs by staining for A2B5, a
putative OPC cell surface marker, after two days of differentiation. Flow
cytometric analysis revealed 60% of lpr NPCs were positive for A2B5, while only
20% of wt NPCs were A2B5-positive (Figure 5a,b).

NPC cell morphology was also confirmed at the protein level using
immunocytochemistry. Staining for βIII-tubulin and PDGFRα corroborated mRNA
expression levels, as the percentage of neuronal cells (βIII-tubulin+) and OPCs
(PDGFRα+) in lpr cultures was double that found in wt (Figure 5c,d).
Altogether, these data indicate that the absence of Fas enhances NPC
differentiation to the neuronal and OPC lineages at both the mRNA and protein
level.

Lpr NPCs exhibit altered levels of neuronal fate specification genes, including
Shh
In search of possible mechanisms and pathways controlling the lpr phenotype,
we ran a “Neurogenesis and Neural Stem Cell” (SA BiosciencesTM) PCR array
using RNA isolated from wt or lpr NPCs after 7 days of differentiation. Of the >80
genes tested, four were down-regulated (apolipoprotein E (Apoe), bone
morphogenetic protein 2 (BMP2), FGF2, S100 calcium binding protein A6
(S100a6)) and 6 were up-regulated (α-filamin (Flna), hairy and enhancer of split 1
(Hes1), Neurod1, Noggin, neuronal pentraxin 1 (NptX1), Shh) in lpr compared to
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wt (Figure 6a). Neurod1, Noggin, and Nptx1 are all genes known to be involved
in regulating neuronal fate specification. Shh is a major modulator of both
oligodendrocyte and neuronal differentiation pathways. The Shh antagonist
BMP2 is down-regulated in lpr NPCs (-3.87 fold, p<0.0012); further indicating
Shh pathway alterations as a probable mechanism for the altered lpr phenotype.
Upregulation of Hes1, Noggin, and Shh was confirmed using RT-qPCR (Figure
6b). To further evaluate the involvement of Shh in the lpr phenotype, we also
tested expression levels of Gli1, a major regulator and target of Shh signaling.
Gli1 was up-regulated 3.86-fold (±0.55) in lpr NPCs compared to wt.

Discussion
There are currently no efficacious treatments for devastating neurodegenerative
diseases including Alzheimer’s and MS. Therefore, there is a pressing need to
develop therapeutics that exhibit neuroprotective effects by acting directly on the
CNS. NPC therapies represent a novel and promising avenue for developing
neuroregenerative treatments (Franklin & French-Constant, 2008; Martino &
Pluchino, 2006). However, all stem cell therapies currently in development
ultimately fail in that they are unable to completely repair lost or damaged CNS
tissue (Blakemore, 2008; Stangel, 2008). If endogenous or transplanted NPCs
could be activated to terminally differentiate, CNS damage and consequent longterm disability could be minimized or even reversed. Therefore, determining
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modulators of NPC differentation and their mechanisms of action is critical to
advancing therapies for neurogenenerative disease.

In this study we have elucidated novel mechanisms for Fas-controlled progenitor
cell behavior. By utilizing a Fas-deficient mutant NPC cell line (lpr), we were able
to determine the significance of Fas-signaling in NPC survival, self-renewal
capacity, and differentiation into the three neuroectodermal lineages. Lpr mice
have a retroviral insertion of poly(A) adenylation signal repeats in the gene for
Fas (Nagata & Golstein, 1995). This large insertion results in improper splicing
and truncation of Fas mRNA so that the cells are devoid of protein expression.
Our study using NPCs isolated from lpr mice is novel in that there has not been
detailed characterization of how lack of Fas affects NPC stemness and
differentiation ex vivo.

We showed that lpr NPCs have dramatically decreased cell death upon
withdrawal of growth factors – a condition that normally induces both significant
cell death and spontaneous differentiation to astrocytes, neurons, and sparse
oligodendrocytes. The significance of this discovery is two-fold. First, this
suggests that Fas manipulation may represent a feasible solution to promote
NPC viability in harsh environments, including that introduced in exogenous stem
cell transplantation paradigms. Second, enhanced survival of NPCs could allow
for enhanced neuroprotective and immunoregulatory capacity in disease models.
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We hypothesize that extended survival of lpr NPCs in the absence of growth
factors increases their capacity for terminal OPC and neuronal differentiation, as
wild-type NPCs are more likely to die before activating differentiation pathways.

This hypothesis is further supported by our data indicating that lpr NPCs have an
increased expression of oligoprogenitor cell (OPC) lineage markers and
enhanced differentiation into mature neurons. Up-regulated OPC marker
expression in lpr compared to wt NPCs was detected by analyzing mRNA levels
using RT-qPCR and confirmed using both flow cytometry surface staining (A2B5)
and confocal microscopy to confirm the OPC phenotype (PDGFRα).

Along with elevated levels of OPC markers, lpr NPCs have elevated levels of
neuronal-specific lineage markers (BIII-tubulin, doublecortin) both at early (two
days) and late (seven days) differentiation time points. In addition, the astrocytespecific marker GFAP remains unchanged. These data indicate a preferential
neuronal-fate specification in NPCs lacking Fas. Corroborating these data, lpr
NPCs show significantly increased expression of genes known to control
neuronal lineage specification and maturation: Noggin, Neurod1, and Nptx1. We
identify Shh, Slit2, and Hes1 signaling as putative upstream regulators of this
neuronally-biased phenotype. Hes1 is a member of the basic helix-loop-helix
(bHLH) transcriptional repressors that regulate cell proliferation and
differentiation during embryogenesis. Levels of Hes1 modulate differentiation of
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ES cells to neuronal and mesodermal cells and oscillating levels contribute to
heterogeneous responses from these cells (Kobayashi et al., 2009). Slit2 acts
through the Roundabout (Robo) receptor and is involved in axon guidance (Lin &
Isacson, 2006; Patel et al., 2001) and neuronal migration (Wu et al., 1999). Shh
is a critical gene involved in patterning during embryogenesis and regulates NPC
proliferation and neurogenesis (Palma et al., 2005; Zhu et al., 1999). Since the
absence of functional Fas in our culture system enhanced neuronal
differentiation, it is possible that active Fas in wt NPCs provides inhibitory signals
against this lineage development. Whether these inhibitory signals act upon the
candidate genes identified here requires further study.

Previously, we (Knight et al., 2009) and others (Corsini et al., 2009) have shown
that activation of Fas via FasL enhances NPC survival. Additionally, in vivo
overexpression of FasL increases subventricular zone neurogenesis. An
explanation for these seemingly contradictory results is that exposure to FasL in
NPCs enhances both survival and neurogenic pathways (Corsini et al., 2009;
Knight et al., 2009); however, the presence of a functional Fas system in the
absence of activating signals (FasL) inhibits these pathways. The latter is
indicated by our current study since endogenous FasL levels are extremely low
in our culture system (Knight et al., 2009) and wt NPCs have decreased survival
and differentiation compared to lpr NPCs – presumably because unactived Fas
serves an inhibitory role in these phenomena. This suggests a dynamic role for
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Fas in both NPC fate specification and survival that is dependent on the
presence or absence of FasL. Taken together, we propose the following
paradigm for the role of Fas in NPCs. Fas targeting leads to two unique
physiological processes: first, Fas ablation promotes NPC survival in deprivedenvironments and second, Fas ablation promotes increased neuronal and oligo
differentiation.

Coupled together, Fas manipulation may produce a viable means of modifying
exogenous stem cell transplantation by overcoming the challenge of cell survival
under harsh transplantation conditions, while promoting complete integration of
NPCs into functional neuronal circuits by stimulation of NPC differentiation. The
Shh signaling pathway, or other molecules identified here, may be a useful target
in promoting this response. This paradigm offers novel candidates deserving
further investigation because of their potential to advance NPC transplantation
therapies.

Conclusion: We have identified Fas as an important modulator of NPC survival,
differentiation, and proliferation. This study is the first to demonstrate a putative
mechanistic link between Fas and Shh signaling. Overall, we provide important
insight into understanding the elusive mechanisms that dictate NPC fatedetermination, an important step in improving NPC-based therapies for
neurodegenerative disorders.
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Methods
NPC Isolation and Culture
NPCs were isolated from whole brains dissected from 4-day postnatal wild-type
C57/BL6 or lpr mutant mice (C57/BL6 background). Brains were processed using
NeuroCult® Enzymatic Dissociation Kit for CNS Tissue (Stem Cell
Technologies). Resulting single-cell suspension was plated in EGF and FGF
(both 10 ng/mL) containing complete media (Gibco®Neural Basal Media
supplemented with B27 and 1:1:2). Neurospheres were chemically dissociated
(Kit, Stem Cell Technologies) into a single-cell suspension and plated on poly-D
Lysine and laminin (both Sigma) coated Nunc® flasks or plates for passaging
and experimentation. Cells were plated at a density of 16,000 cells/mL media
and grown to confluency (3-4 days) before experimentation or switching to
minimal media. All experiments were performed on passage-matched wt or lpr
NPC lines and only cells with passage numbers between 3 and 6 were used.
Proliferation studies were performed in EGF and FGF containing media, cell
death studies and early differentiation timepoints were performed in minimal
media (Neural Basal Media with only B27 and 1:1:2 [penicillin/streptomycin: Lglutamine: glucose]), and extended differentiation experiments were performed in
minimal media containing 0.2% FCS (to prevent extensive cell death in the
absence of growth factors). All cells incubated in 37°C/5% CO2 conditions.
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Flow Cytometry
Cells were lifted using 0.05% trypsin/EDTA (Gibco) at 37°C. Trypsin enzyme was
stopped using 20% FCS/neural basal media after 7 mins. Cells were placed in
Falcon® tubes (#352058) and then rinsed with 1XPBS and spun at 1400 rpm
before proceeding with staining. All stains were added to a 100 µL volume cell
suspension containing approximately 1x106 cells.

Fas receptor stain
Samples blocked with hamster IgG (50 ug/mL). Samples stained with either antiFas or isotype control (Hamster IgG2, λ1) phycoerythrin (PE)-conjugated
antibodies (1:30, BD Biosciences). All rinses and dilutions were done with
1%BSA/1XPBS. All incubations performed at 4°C (15 min for block, 30 min for
PE-conjugated antibodies).

A2B5 stain
Biotynlated anti-A2B5 (50 uL, 1:100, BD Pharm) added to each sample. Primary
antibody incubated for 30 min at 4°C. After rinsing with PBS, StrepavidinPhycoerythrin (100uL, undiluted, BD Pharm) added to each sample and
incubated for 30min at 4°C. Samples rinsed twice before analyzing on flow.
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Controls included : no primary and a sample of NPCs growing in the presence of
EGF and FGF (to serve as a low percent differentiation negative control).

Death & Apoptosis Assay (UV/Annexin stain)
UV Live/Dead Dye® and Annexin Alexa Fluor-647 both used according to
manufacturer instructions (Invitrogen). Briefly, 200 µL of diluted UV dye (2 µL per
mL 1xPBS) was added to cell suspension containing 10,000 cells/µL. Cells were
incubated on ice, in the dark, for 30 min. After cells with 1xPBS and aspirating
the supernatant, 100 uL of diluted Annexin (1 µL per 400 µL HEPES buffer) was
added to cells. Cells grown in complete media (growth factors present) were
used as a negative control because >90% of cells in these cultures are
live/healthy. Cells briefly treated with 3% paraformaldehyde were used as
positive controls because >90% of cells are dead/dying.

Cell Proliferation: BrDU assay performed according to manufacturer instructions
(FITC Detection BrdU Flow Cytometry Assay Kit, BD Biosciences). Briefly, cells
were first pulsed overnight (16 hours) with BrDU and subsequently fixed and
stained with a FITC-conjugated anti-BrDU antibody for flow analysis. Cells
grown in minimal media (no growth factors) were used as a negative control
because <10% of cells grown in these conditions will stain positive for BrDU
incorporation.

106

Analysis
Flow cytometry analysis was performed by a BD LSRII flow cytometer equipped
with 3 lasers (488, helium neon, and UV) and data were analyzed with FlowJo
software, respectively.

Neurosphere self-renewal assay
Single-cell suspensions were plated in uncoated 24-well plates (seeding density
of 100,000 cells/mL) using NPC media containing EGF and FGF. After 7 days, 23 pictures of random frames from each well (3 wells per cell type) were taken at
20X using a phase-contrast microscope. After taking pictures, neurospheres
were dissociated using Neurocult® Chemical Dissociation Kit and then filtered
through a 40 µm nylon cell strainer (BD FalconTM). Cells were then counted,
plated as described above, and grown for 7 days before the next passage time
point was recorded (this same process completed four total times over four
weeks). Cell circumferences were measured using Neurolucida software.

Immunocytochemistry
Cells were plated in 24-well plates with poly-D/Laminin coated coverslips and
grown to confluency. At this point, cells were rinsed and allowed to differentiate 1
week in minimal media containing 0.2% FCS. For all differentiation markers, 3
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coverslips were scored per cell line and repeated for at least 3 biological
replicates.

Stains performed as follows: Cells fixed with Zamboni’s fixative and blocked
(10%HS/0.1% Triton/0.02% Azide in 1XPBS) for 30 min. Both primary and
secondary antibodies diluted in block. Block for PDGFRα stain did not include
triton. Primaries incubated overnight at 4C, while secondary antibodies
incubated for 1.5 hrs at RT. Cells rinsed 3X between primary and secondary. All
cells counterstained with Hoechst nuclear stain (1:2000). The following
antibodies were used: rabbit anti-BIII Tubulin (Sigma, 1:100), rabbit anti-PDGFRα
(Santa Cruz, 1:50), rabbit anti-GFAP (Dako, 1:1000), goat anti-rabbit Cy3 (1:500,
Jackson Immunoresearch).

All confocal images were acquired using the “Tile” feature on a Zeiss LSM 510
META confocal laser microscope. Cells were visualized on the left side of each
cover slip at 20x magnification, and then the microscope acquired 16 consecutive
field-of-view images in the form of a 4x4 square (referred to here as a tile). The
field-of-view was then reset to a visual field directly to the right of this tile, on the
same horizontal plane as the previous tile. This new tile was acquired, and the
procedure was repeated until enough tiles were acquired to span the horizontal
diameter of each coverslip. All cell scoring was performed using ImageJ
software. Each tile was scored for the number of nuclei present (hoechst positive
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cells) and the number of cells staining positive for the respective differentiation
marker. To ensure that we scored every cell spanning the complete horizontal
diameter, tiles were acquired with slightly overlapping fields of view on the left
and right sides. Adjacent tiles were then viewed side-by-side and the overlapping
regions were removed from only one tile, thereby ensuring that every field-ofview was acquired and that cells in overlapping fields of view were scored only
once. At least 9 tiles were acquired and tallied per slip, resulting in the total
acquisition of > 75 individual fields-of-view per coverslip . All data is presented as
the percentage of positive cells per the total cell count spanning the horizontal
diameter.

RT-qPCR and Gene Expression Arrays
Performed as previously described (Knight, et al., 2009). Briefly, RNA was
extracted from cells using RNeasy® Mini Kit (Qiagen) according to manufacturer
protocol. For RT-qPCR, cDNA was prepared using Superscript® III First-Strand
Synthesis Supermix for qRT-PCR. RT-qPCR completed using Taqman® Master
Mix and applied Biosystems 7500 Fast Software. Primers were purchased from
Applied Biosystems (Taqman Assay on Demand). Neurogenesis and Neural
Stem Cell (PAMM-404) PCR arrays purchased from SA BiosciencesTM and RNA
samples were processed by UVM Cancer Center DNA Facility.
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Statistics
Graphs were created and statistical analyses were run using GraphPad Prism
software. Student’s t-test or ANOVA with Tukey’s post-test were used to
determine significance (p-values).
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Figure 3-1: lpr NPCs lack Fas
Lpr mice have a large insertion in the Fas gene which results in improper splicing
and absence of the protein. We confirmed absence of Fas in lpr NPC using a
phycoerythrin (PE)- conjugated anti-Fas antibody. Background staining was
assessed using a isotype control IgG antibody (blue line). Unlike wild-type NPCs
(green line), lpr NPCs (red line) do not express Fas (+ peak completely overlaps
with isotype control). Y-axis represents % of maximum staining intensity (arbitray
units) while the X-axis represents the voltage of positive PE fluorophore staining.
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Figure 3-2: Abrogated proliferation and sphere growth in lpr NPCs
(a-f) all experiments performed in complete media (presence of EGF and FGF).
(a) Cells growing in medium were pulsed overnight with BrDU. Proliferating cells
were detected using a FITC-conjugated anti-BrDU antibody (*p<0.05, n=4). (b)
light microscope pictures of 7 day old tertiary neurospheres growing in complete
media. (c) and (d) Neurosphere self-renewal assay: sphere size and number was
quantified over 4 passages starting with passage 2 cells. Cells were dissociated
and re-plated at each passage (i.e. every 7 days). n=6 separate wells from 2
independent experiments. (c) Neurosphere size quantification using
Neurolucida® software. Lpr neurospheres were significantly smaller than wildtype at passage number 3, 4, and 5 (*p<0.05) (d) Quantification of neurosphere
number. Shown is the average number within 20X phase microscope images (as
shown in (b)). (e) and (f) representative histograms of cells growing in complete
media for four days. Y-axis represents dead cells (staining positive for UV
Live/Dead dye) and X-axis represents apoptotic cells (staing positive for annexinAlexaFluor647). The majority of cells are live/healthy (lower left quadrant), with
no differences between lpr (e) and wt (f) samples.
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Figure 3-3:Fas-deficient NPCs have increased survival in the absence of
growth factors
Cultures were switched to minimal media (no EGF or FGF) for 48 hrs and then
the apoptosis (Annexin) and death (UV dye) assay was performed and analyzed
using flow cytometry. (a) Plotted are the percentages of healthy cells, which are
negative for either stain. n=5 (# independent experiments), error bars represent
SEM. p<0.01. In representative phase microscope images (b), bright and floating
bodies represent dead cells (indicated by smaller, red arrows) while attached
cells with processes represent live/healthy cells (indicated by larger, green
arrows).
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Figure 3-4: lpr NPCs are more committed to oligo- and neuronal lineages
(a) Spontaneous differentiation of lpr cells compared to wt after 2 days in minimal
media. (b) Summary of lineage marker results at 2 days (minimal media) and 7
days (0.1% FCS). Fold changes are lpr expression levels relative to wt.
Each represented fold difference reached statistical significance (p<0.05, n=5
independent experiments). Fold changes calculated using 2 -ΔΔCt method with βactin as the endogenous control gene and wt NPC samples as the calibrator
(mRNA expression levels set to equal 1).
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Figure 3-5: lpr NPCs have enhanced differentiation into Neuronal and OPC
lineages
(a) Representative fluorescence histogram for A2B5 positivity after 2 days in
minimal media. Complete media was used as a negative control because no
differentiation is expected in the presence of growth factors. (b) Quantification of
A2B5 flow data (n=4 independent experiments, p<0.01). After 3 days of
differentiation (right columns), lpr NPC still expressed a significantly higher
amount of A2B5, though overall levels of this marker is decreased in both cell
types. (c & d) Immunocytochemistry was performed on cells after seven days in
differentiating media. (c) Differentiation of wt (top panels) and lpr (bottom panels)
into neurons (βIII-tubulin+ cells, left panels) and OPCs (PDGFRα+ cells, right
panels). (d) Quantification of IHC data using ImageJ software. Percent positive =
# lineage marker+/total # of Hoechst+. 12-14 serial photos were taken from 3
separate coverslips. p<0.05, n=3.
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Figure 3-6: Upregulation of Shh and neuronal specification genes in lpr
NPCs
(a) Shown are genes with significant mRNA fold-changes (out of >80 tested, SA
BiosciencesTM “Neurogenesis and Neural Stem Cell” PCR Array) in lpr NPCs
compared to wt NPCs after seven days in differentiation medium. Downregulated genes (red font) have been converted to whole numbers via
1/[fractional fold change]. (b) RT-qPCR confirmation of gene upregulation in lpr
NPCs after one week in differentiation media. Data are based on 4 biological
replicates (n=4), all fold changes are significantly above levels in wt cells
(p<0.01).
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Abstract
Immune-neural interactions dictate both lesion formation and repair in multiple
sclerosis (MS). MS pathogenesis is mediated by the interplay of invading
immune cells, neurons, glia, and endogenous stores of neural stem/progenitor
cells (NPCs). However, the signals important in this cross-talk are not well
defined. We utilized a co-culture method and flow cytometric analysis capable of
detecting outcomes for both cell types. Here we describe the effects of NPCs on
three different CD4+ subtypes (Th1, Th2, and Th17) and vice versa. Utilizing lpr
(Fas receptor-deficient) and gld (Fas ligand-deficient) NPC lines, we further
define the role of Fas in this neuroimmune cross-talk. We show that only the Th1
subtype is capable of inducing NPC cell death, and this is independent of Fas
activation. Conversely, NPCs specifically kill pro-inflammatory Th1 and Th17
cells in a contact-dependent manner without affecting Th2 survival. Further
investigation into these effects revealed that FasL expressed by NPCs mediates
Th17 apoptosis. Additionally NPC/T-cell cross-talk modulates FasL expression in
both cell types, while Fas receptor levels remains static. These findings illuminate
the direct neuropathogenic effects of T-cells, as well as help define the
immunomodulatory capacity of NPCs. We have elucidated novel interactions that
may be critical in MS pathogenesis.

Introduction
MS pathogenesis is mediated by complex interactions between invading immune
cells, neurons, glia, and endogenous stores of neural stem/progenitor cells
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(NPCs). Though remyelination occurs early in MS disease course, ultimately the
endogenous stores of NPCs are unable to sustain full neuroprotection and repair
(Pluchino et al., 2004). Subventricular zone NPCs have the ability to migrate to
white matter lesions, though their exact neuroregenerative capacity remains
unknown (Picard-Riera et al., 2002, Menn et al., 2006, Blakemore, 2008).
Repeated bouts of inflammation have been indicated in altering NPC
homeostasis, and may contribute to disease pathogenesis (Pluchino et al.,
2008). Both NPC niche architecture and migratory capacity are altered by
repeated inflammation (Pluchino et al., 2008). A detailed understanding of the
cross-talk that occurs between NPCs and immune cells is critical for developing
neuroprotective therapeutics that could be directed at mobilizing or replacing lost
NPC regenerative capacity.

NPC transplantation therapy has shown significant promise in the animal model
of MS, experimental autoimmune encephalomyelitis (EAE). Animals receiving
either intraventricular or intravenous injections show clinical recovery and
immunopathologically have decreased CNS immune infiltration, inflammation,
and axonal damage (Einstein et al., 2003, Pluchino et al., 2003, Pluchino et al.,
2009a). The primary mechanism for disease recovery is via bystander
immunomodulatory functions that decrease inflammation (Pluchino et al., 2005,
Einstein et al., 2006). Though transplanted NPC clinical effectiveness and
immunomodulatory capacity is well documented, the exact mechanisms that
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dictate these effects are not fully understood. NPCs exert immunoregulatory
functions partially via disruption of activated T-cell expansion. The ability of
murine and human NPCs to decrease the proliferation of T-lymphocytes has
been shown both in vitro and in vivo (Aharonowiz et al., 2008, Fainstein et al.,
2008, Pluchino et al., 2009b, Wang et al., 2009). Furthermore, NPCs induce cell
death specifically in pro-inflammatory Th1 cells via upregulation of various death
receptors, including Fas (Pluchino et al., 2005). The complex immunoregulatory
capacity of NPCs is beginning to be uncovered; however, the converse
interaction – effects of specific T-cell subtypes on NPCs – has not been
previously described. In this study, we set out to define the critical factors
involved in the two-way interaction between NPCs and CD4+ T-cell subtypes
(Th1, Th2, and Th17). To date, no one has studied the communication between
NPCs and pro-encephalogenic Th17 cells.

Our lab and others have investigated the role of Fas (a member of the TNF
receptor family) in NPC physiology. Fas has a well-established role in the
immune system maintaining T-cell homeostasis via apoptotic mechanisms
(Nagata and Golstein, 1995). In contrast to the immune system, Fas expression
and activation has complex and multifaceted roles in NPC biology (Corsini et al.,
2009, Knight et al., 2009). The exact role of Fas/FasL in the nervous system
appears to be different depending on both the type of cell and maturity stage of
cell (i.e. functional neuron versus immature NPC). The well-described functions
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of Fas in the immune system as well as its novel functions in NPCs lead us to
explore whether Fas was a critical player in immune cell/NPC cross-talk. Here we
describe novel communications between NPCs and T-cell subtypes. Our data
show Th1 cells alone induce dose-dependent NPC cell death. NPCs have a twofold effect on pro-inflammatory cells. Firstly, they kill Th1 cells in a dosedependent and contact-dependent manner. Secondly, NPCs cause a
pronounced induction of pro-encephalogenic Th17 cell death via a Fas/Fas
ligand-dependent mechanism. NPCs have no effect on anti-inflammatory Th2
survival. Overall, we have elucidated detailed and complex mechanisms
responsible for NPC immunomodulatory capacity and shed light on the
previously unexplored ability of T-cells to directly influence NPCs.

Materials and Methods
NPC Isolation: NPCs were isolated and characterized as previously described
(Knight et al., 2009). Briefly, brains were dissected from 4-day post-natal C57/Bl6
mouse pups. NPCs were extracted using NeuroCult® Enzymatic Dissociation Kit
(Stem Cell Technologies) and plated in complete neural basal media
(Gibco®Neural Basal Media supplemented with EGF, FGF, B27 and 1:1:2
[penicillin/streptomycin: L-glutamine: glucose]) and expanded in culture as
neurospheres. Neurospheres were enzymatically dissociated into a single-cell
suspension, and then grown as a monolayer on Poly-D-lysine and Laminin (both
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Invitrogen) coated plates before experimentation. Only NPCs at passage number
4-6 were used for co-culture experiments.
NPCs were isolated from wild-type (abbreviated “WT”) C57/BL6 mice, lpr (Fasdeficient) mutant mice, and gld (fas-ligand deficient) mutant mice. Lpr and gld
mutant mice are in a C57/Bl6 background. In order to be able to gate the NPC
population specifically within co-culture flow experiments (see below), NPCs
were stably transduced with the DsRED2-mito transgene cloned from a vector
containing reef coral fluorescent protein as previously described (Spees et al.,
2006). After transduction, DsRED NPCs were sorted using FACS® to obtain a
purity of 85-95% red cells. Purified cells were expanded before experimentation.

T-cell Isolation and Polarization: Total T-cells were obtained from mechanically
dissociated lymph nodes (inguinal, mesenteric, periaortic) and spleens of 7-10
week old wild-type C57/BL6 mice. Blood cells were lysed within spleen
homogenates using Geye’s solution. CD4+ population was purified using mouse
CD4+ isolation kit (Miltenyi Biotech) and MACS® magnetic separation columns
according to manufacturer instructions. To ensure purity, an aliquot of cells was
subjected to CD4+-surface staining (FITC-conjugated anti-CD4 antibody, BD). All
T-cell collections used for co-culture experiments had >90% purity.
Naïve CD4+ cells were plated (1x106 cells/ml) in complete T-cell media (RPMI
supplemented with Folate, L-glutamate, glucose, 10% FCS,
penicillin/streptomycin, and β-mercaptoethanol). T-cells were immediately
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stimulated with soluble 2 µg/ml anti-CD28 and plate-bound anti-CD3 (5 µg/mL )
at time of polarization. T-cell polarizations were performed according to
previously established protocols (Noubade et al., 2007). For polarizations to each
cell type, cytokines were added as follows: Th1 - 10 µg/mL anti-IL4 & 4 ng/ml IL12; Th2 - 10 µg/ml anti-IFNγ & 30 ng/ml IL-4; Th17 - 30 ng/ml IL-6, 1 ng/ml
TGFβ, 10 µg/ml anti-IFNγ, and 10 µg/mL anti-IL4. After stimulation period (three
days for Th1 & Th17, four days for Th2), T-cells were re-stimulated with plate
bound CD3 for 24 hours. Anti-IFNγ and anti-IL4 were purchased from BD
Pharmingen, all other cytokines from Peprotech.

ELISA: Reagents and components for ELISA were purchased from R&D. A 96well plate was coated overnight with capture antibody (for IL-4, IFN-gamma, or
IL-17) at 2 ug/mL at room temperature. Plates were washed and blocked with
block (filtered 1% BSA in 1x PBS) for 1 hour. T-cell supernatants (collected postpolarization and restimulation) were then added at dilutions of 1:2, 1:4 and 1:8,
and a standard curve was constructed in the first 3 well columns. After 2 hours
at room temperature, the plate washed and detection antibody was added and
allowed to sit for two hours. Wells were washed, and streptavidin- horseradish
peroxidase was added for 45 minutes. After another wash, substrate solution
(H2O2/tetramethylbenzadine) was added until the reaction developed. Stop
Solution (2N H2SO4, R&D DY994) was added to each well and the plate was
read on a microplate reader at 540 nm.
128

Co-Cultures: Single-cell suspension of NPCs were plated at a density of 16,000
cells/mL in 24-well plates and grown for 3-4 days (~85% confluency) in complete
neural basal media. At that point, the monolayer of NPCs was rinsed 2X and then
re-stimulated T-cells were added in either 1:1, 1:3, or 1:5 ratios (NPC: T-cell. All
co-culture experiments and control samples were cultured in modified T-cell
media (RPMI, Pen/Strep, L-Glutamate, 5% FCS). These culture conditions were
chosen because NPCs did not survive optimally in complete T-cell media (see
above) and T-cells did not survive in serum free NPC media (data not shown).
Each well of the 24-well plate contained 0.2x106 NPCs; therefore, 0.2x106,
0.4x106, or 1x106 T-cells were added to obtain appropriate ratios (1:1, 1:3, and
1:5, respectively). Total volume of co-cultures was 1mL. NPC or T-cell control
wells contained only a single cell-type in modified T-cell media. Assays were
performed after 48 hours of co-culture. Transwell experiments were performed by
placing T-cells within NUNC™ inserts (0.4 µm membrane).

Assays: Flow cytometric evaluation of apoptotic and dead cells was performed
with Annexin V Alexa Fluor-647 Conjugate assay and LIVE/DEAD bluefluorescent reactive dye kit, respectively (both Invitrogen), according to
manufacturer instructions. UV Live/Dead dye is a viability dye that stains dead
cells with compromised cell membranes. It only identifies dead cells, and does
not discriminate between apoptosis or necrosis. Annexin binds strongly to
129

phosphatidylserine residues on the surface of early apoptotic cells. One of the
first stages of apoptosis includes loss of the asymmetry of the inner and outer
layers of the cell membrane (i.e. phosphatidylserine flipping to the exterior
surface of the cell).

To differentiate between NPC’s and T-cells, T-cells were stained with anti-T-cell
receptor (TCR)αβ (Cytochrome 5.5 conjugated), and NPCs had been previously
transduced with the DsRED fluorescent transgene (see above). Dead cells
commonly stain non-specifically for receptor stains such as TCR. There is a
small (5-8%) population of TCR+ staining stem cells (Figure 1A), but this staining
is non-specific because gating exclusively this population reveals only dead cells
(data not shown). No live NPCs stain positive for TCR+ staining.

Flow Cytometry: Flow cytometry analysis was performed by a BD LSRII flow
cytometer equipped with 3 lasers (488, helium neon, and UV), and data were
analyzed with Flow Jo software, respectively.

RT-qPCR: RTqPCR was performed as previously described (Knight et al., 2009).
Briefly, RNA was extracted from cells using RNeasy® Mini Kit (Qiagen)
according to manufacturer protocol. For T-cell RNA, supernates from co-cultures
(containing T-cells floating in suspension) were spun at 1,200 rpm for 6 min;
supernate was then removed and the T-cell pellet was used for RNA extraction
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protocol. For NPC RNA, supernates were removed and monolayer cells were
washed to remove dead cells or T-cells that may have stuck to the surface before
continuing with RNA extraction protocol. Control cells (either NPCs or T-cells)
were cultured in modified T-cell media alone.

cDNA was prepared using Superscript® III First-Strand Synthesis Supermix for
qRT-PCR. RT-qPCR completed using Taqman® Master Mix and applied
Biosystems 7500 Fast Software. Primers for Fas and FasL were purchased from
Applied Biosystems (Taqman Assay on Demand). β-actin was used as an
endogenous control gene for all experiments. Three biological replicates were
pipetted in duplicate for each sample.

Data Analysis: All graphs prepared and statistical analyses were run using
GraphPad® Prism software. Note that “n” refers to the number of independent
experiments. ANOVA and Bonferroni’s post-test were used to determine
significance.

Results
Optimal T-cell Polarization Protocol
T-cell subtypes are stratified according to their cytokine expression profile. In
order to ensure T-cells were efficiently polarized to each respective subtype,
following the polarization and restimulation process, supernatants were collected
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and stored at -80 for characterization using ELISA. Each sample was subjected
to a cytokine profile to determine levels of IFN-gamma, IL-4, and IL-17. Only Th1
cells produced IFN-gamma (Figure 2A), only Th2 cells produced IL-4 (Figure 2B),
and only Th17 cells produced IL-17 (Figure 2C).

Effects of Immune Cell on NPCs
To determine the direct impact of each T-cell subtype on NPC viability, we
analyzed the NPCs specifically within the co-culture based on red
autofluorescence (DsRED+/TCR- cells; Figure 1A, top gate). NPCs were
analyzed after a 48-hour co-culture with each polarized and stimulated CD4+
subset. Viability was assessed using UV live/dead dye (dead cells and annexin
(apoptotic cells) co-staining (Figure 1B).
The percentage of live/healthy NPCs (staining negative for either dye) remained
unchanged in both Th2 (Figure 3A) and Th17 (Figure 3B) co-cultures, indicating
that neither Th2 nor Th17 have the capacity to induce NPC apoptosis.
Conversely, Th1 cells produced a dose-dependent induction of NPC apoptosis,
indicated by a decreased percentage of live/healthy NPCs with higher T-cell
ratios (Figure 4A). 1:1, 1:3, and 1:5 Th1 co-cultures reduced the percentage of
live/healthy NPCs from 87% to 66%, 54%, and 39%, respectively.

To determine whether the ability of Th1 cells to induce NPC death is dependent
on cell contact or mediated by a secreted factor, we utilized a transwell system

132

where only media is exchanged between cell types. Th1-mediated NPC
apoptosis is dependent on cell contact, as the effect is negated in transwell cocultures (Figure 4B), indicating the phenomenon is likely mediated by a factor
expressed on the surface of Th1 cells.

In order to assess the importance of NPC Fas-receptor expression in cross-talk
interactions, co-cultures were performed using wild-type or Fas-deficient (lpr)
NPCs concurrently. Th1 induction of NPC apoptosis is not mediated by Fas, as
lpr NPCs had the same amount of death as wild-type NPCs at varying Th1 ratios
(Figure 4B).

Effects of NPCs on immune cells
To determine the effects NPCs have on each CD4+ cell type, co-cultures and
staining were performed as described above, but only the DsRed -/T-cell
receptor+ population of cells (identified by using a Cy5.5 conjugated anti-TCRαβ
antibody) was analyzed (Figure 1A, bottom gate).
NPCs induced dose-dependent death of Th1 cells (Figure 5A), evidence by
increased Th1 death with higher proportions of NPCs. NPCs decreased the
viability of Th1 cells by 23% and 20% at 1:1 and 1:3 ratios, respectively. Th1 cell
viability at the lowest proportion of NPCs (1:5) trended downward, but was not
statistically significant. NPCs caused a pronounced induction of Th17 cell death,
and this effect was not dose-dependent (Figure 5B). The percentage of
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live/healthy Th17 cells was reduced by approximately 45% in NPC co-cultures at
all ratios. NPCs did not influence Th2 cell survival (Figure 5C). Taken together,
this data shows NPCs negatively regulate pro-inflammatory Th1 and Th17 cell
types without effecting anti-inflammatory Th2 cells.

No differences were observed between the ability of wild-type and lpr NPCs to
affect any T-cell subtype (Figure 5A-C). Therefore, the immunoregulatory
capacity of NPCs is independent of their Fas-receptor expression.

Mechanism for NPC-mediated Th17 apoptosis
As Th17 cells are debated to be the most encephalogenic cells in MS, we were
interested in further investigating the distinctive ability of NPCs to induce Th17
cell death. Th17 apoptosis was abrogated in transwell cultures (Figure 6),
indicating this effect was cell-contact dependent. Since our lab previously
determined the importance of Fas in NPC physiology, and Fas is a major
regulator of autoreactive T-cell in the immune system, we hypothesized the
ability of NPCs to kill Th17 cells was mediated by Fas/FasL. In order to test this
hypothesis, co-cultures were performed with gld (FasL-deficient) NPCs. FasLdeficient NPCs lost their ability to kill Th17 cells (Figure 6). Therefore, in contrast
to Fas-receptor expression, FasL expression on NPCs is critical to their ability to
immunoregulate via Th17 supression.
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Co-culture influence on Fas/FasL Expression levels
Expression levels of both the Fas receptor and its cognate ligand (FasL) may
influence the results of our co-cultures. Futhermore, Fas/FasL expression on
NPCs/T-cells may change upon exposure to the other cell type. To explore this
possibility, mRNA was extracted from NPCs and T-cells either in co-culture or in
media alone (controls) conditions. This mRNA was subjected to RT-qPCR to
determine levels of both Fas and FasL.

mRNA expression levels of Fas in both NPCs and T-cells remained unchanged
in co-culture samples in comparison to controls of each cell type alone. ΔCt
values for Fas in NPCs remained at 5.90±0.22 in controls and co-cultures, while
ΔCt values in T-cells remained at 9.02±0.34in all samples (regardless of T-cell
subtype or culture condition). Therefore, Fas receptor expression remains
constant in our co-culture system and Fas expression dose not vary in within the
different T-cell subtypes.

Comparing FasL levels in T-cell subtypes reveals that Th1 cells produce the
highest levels of FasL (Figure 7A). Th1 T-cells produce approximately 6-fold
higher levels of FasL compared to Th17 cells. FasL expression levels in Th2 cells
lies in between those found in Th1 cells and Th17. This differential FasL
expression between subtypes may explain the fact that Th1 control cultures have
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significantly more baseline cell death compared to Th17 cultures. Th1 and Th17
T-cell alone control cultures have 60% and 80% live/healthy cells, respectively
(Figure 5A,B). Death induction via T-cell expressed FasL is a well characterized
mode of autoregulation and maintaining homeostasis within the immune system
(Nagata and Golstein, 1995).

Co-cultures with Th1 cells dramatically increase the NPC expression of FasL in a
dose dependent manner (Figure 7B). The 1:1 ratio of NPCs to T-cells increased
NPC FasL expression 16-fold compared to NPC control cultures, while the 1:3
ratio increased expression approximately 30-fold. Th17 cells appear to have a
more modest effect on NPC FasL expression, as significant effects were only
seen at the 1:3 ratio. 1:3 co-cultures enhanced NPC FasL expression levels by a
factor of 2.3±0.22 (p<0.05).

In contrast to NPCs, FasL levels in Th17 cells is decreased in co-cultures
compared to Th17 control samples (Figure 7C). This effect is dose-dependent,
as the 1:3 ratio (1NPC: 3TC) exhibited a 2.2-fold (±0.17) decrease in Th17 FasL
expression and the 1:1 ratio (1NPC: 1TC) decreased FasL expression 4.2-fold
(±0.29). Since FasL can be toxic to neurons and oligodendrocytes (Li et al.,
2002, Giuliani et al., 2003), NPC-mediated downregulation of FasL in
proinflammatory T-cells could be a novel mechanism for immunomodualtion and
supporting neuroprotection. Th1 FasL levels trended downwards in co-cultures in
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comparison to Th1 controls, however this difference was not statistically
significant at either ratio.

Discussion
This study demonstrates that there is direct influence of inflammatory cells on
NPCs. This phenomenon could reflect critical interactions with endogenous
NPCs in MS disease lesions. Our work is novel in that it is the first to investigate
the effects of specific T-cell subtypes on NPCs. T-cell effects on NPCs were only
observed in Th1/NPC co-cultures, where Th1 cells caused dose-dependent NPC
apoptosis. These effects are cell contact-dependent and Fas-independent. Since
Th1-mediated NPC death requires cell contact, it is likely that a factor expressed
on the Th1 cell surface induced this effect. As Th1 cells were the only CD4+
subtype to induce NPC death, this factor must be specific to Th1 cells. Further
investigation into this mechanism will shed further light on how inflammatory cells
can directly damage the endogenous NPC niche.

Secondly, our results present a detailed mechanism for the robust
immunoregulatory properties of NPCs. Overall, our data indicate that the
immunomodulatory capacity of NPCs seen in previous EAE studies likely stems
from their ability to selectively delete pro-inflammatory T-cells, as opposed to
supporting anti-inflammatory Th2 cells (Figure 8). We found that NPCs
selectively kill pro-inflammatory Th1 and Th17 cells, and do not influence Th2 cell
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death. Interestingly, interactions with Th1 T-cells enhanced FasL expression in
NPCs in a dose-dependent manner. A smaller induction of FasL was also seen in
Th17 co-cultures at the higher concentration. This phenomenon may serve to
enhance NPC-mediated killing of proinflamatorry T-cells, as higher
concentrations of T-cells signal to the NPC that more FasL is required for
immunomodulatory efficiency. Both Th1 and Th17 cells are considered to be the
main mediators of disease pathogenesis in MS. In our study, NPCs were able to
induced dose-dependent apoptosis in Th1 cells. This result is in line with
Pluchino’s work that showed NPCs induce selective Th1 apoptosis without
influencing Th2 cells (Pluchino et al., 2005). This effect was modulated by upregulation of specific death receptors (FasL, TRAIL, and APO3L) on the surface
of NPCs (Pluchino et al., 2005). The beneficial anti-inflammatory effects of NPCs
paired with their capacity to home specifically to lesions within the CNS (Ben-Hur
et al., 2003, Pluchino and Martino, 2005) make them a promising candidate for
therapeutic intervention. The fact that NPCs follow chemokine and cytokine
gradients to enter the damaged CNS (Pluchino et al., 2005, Pluchino et al.,
2009a), along with their ability to persist for long periods of time within the brain
parenchyma (Pluchino et al., 2009a),may allow for enhanced, targeted
neuroprotection compared to currently used systemic therapies.
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Our data show NPCs induce a dramatic induction of pro-encephalogenic Th17
cell death. This effect is cell-contact dependent and is mediated via NPC
expression of FasL. Robust deletion of Th17 cells by FasL expressed on the
NPC surface is a novel mechanism for NPCs supporting an anti-inflammatory
environment and neuroprotective functions. Our findings that NPCs can also
down-regulate FasL expression on Th17 cells may further contribute to
neuroprotection since T-cell expression of FasL has been associated with
neuronal and oligodendrocyte death (Li et al., 2002, Giuliani et al., 2003). These
results are speculative, however as cell preparations from which mRNA was
isolated may include dead NPC cell mRNA. NPC effects on Th17 cells have the
most prominent potential implications for MS, as the Th17 subtype is now
considered central to the development and progression of inflammatory lesions.
Most data supporting this view comes from EAE studies. EAE can be induced by
passive transfer of IL-17 producing, activated CD4+ cells (Langrish et al., 2005).
Mice deficient in IL-12 or IFNγ, factors known to suppress IL-17 production,
exhibit exacerbated EAE (Murphy et al., 2003, Langrish et al., 2005).
Furthermore, blocking the p40 subunit of the IL-17 receptor with administered
antibodies decreases EAE severity (Cua et al., 2003, 't Hart et al., 2005). Support
for these findings having clinical importance in humans comes from MS lesion
studies. IL17+ cells have been found in active MS lesions (Tzartos et al., 2008),
and receptors for Th17 cytokines (IL-17 and IL-22) have been identified within
MS lesions (Kebir et al., 2007). Both IL-6, which promotes Th17 differentiation,
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and IL-17 gene transcripts are increased in acute lesions (Lock et al., 2002). If it
is true that Th17 cells are critical in MS pathogenesis, our data indicate that
NPCs may be particularly effective as a therapeutic approach because they can
specifically target and delete this encephalogenic cell type.

Fas-induced apoptosis via FasL is a well established mechanism of maintaining
homeostasis within the immune system (Nagata and Golstein, 1995). Unlike
NPCs, T-cells are very sensitive to FasL induced cell death (Knight et al., 2009).
It is likely that FasL expressed by the T-cells themselves results in some T-cell
apoptosis in our co-culture system. As 20% of Th17, 25% of Th2, and 40% of
Th1 cells are dead/dying at baseline (T-cell alone controls- See Figure 5), it is
plausible to assume at least some of this death is caused by T-cell expression of
FasL. Considering Th1 cells express much higher levels of FasL compared to
either Th2 or Th17 (Figure 7A), this may be an explanation for the increased
death seen in Th1 control cultures (compare Figure 5A to 5B or C).
Interactions between endogenous NPC populations and invading immune cells
may have a critical role in both ameliorating inflammatory damage and repairing
damaged tissue in MS. Recent evidence suggests that subventricular zone
(SVZ)-derived NPCs may contribute to remyelination in both inflammatory and
toxic demyelinating rodent models (Picard-Riera et al., 2002, Menn et al., 2006,
Blakemore, 2008). Since inflammatory demyelinating lesions accumulate over
time in the SVZ of MS patients, it can be hypothesized that an alteration of the
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functionality of SVZ-resident NPCs may contribute to remyelination failure in MS.
The main potentially clinically relevant point of contact for NPC/immune cell
cross-talk is the MS lesion site. Both SVZ and spinal cord NPC have the ability to
migrate to lesion sites in EAE (Picard-Riera et al., 2002, Brundin et al., 2003).
Furthermore, cells positive for the NPC marker NG2 have been identified within
lesion sites in MS patient tissue (Chang et al., 2000). On the immune side of
cross-talk, there is striking evidence for CD4+ infiltrates in acute MS lesions, and
to a lesser extent in chronic lesions (Stadelmann and Brück, 2008, Tzartos et al.,
2008). Additionally, both T- and B-cell infiltrates correlate with activity in
demyelinating lesions (Frischer et al., 2009). Importantly, neurodegeneration
correlates with inflammatory markers throughout early and late stages of disease
(Frischer et al., 2009). Therefore, understanding the neural-immune interface is
crucial for developing strategies that can mitigate the axonal damage that occurs
during relapsing-remitting disease, and also the chronic neurodegeneration that
occurs in secondary-progressive phases. Although our study is limited in that we
present only in vitro data, an advantage of this system is the ability to articulate
the communications between specific cell types and elucidate the factors that
dictate these interactions. Since our co-culture system serves as a model for
phenomena that occur within the inflamed CNS, the neuroimmune cross-talk and
factors described here may have relevance for therapeutic intervention.
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In summary, elucidating the specific signals that dictate communications at the
neural-immune interface will allow for greater understanding of both NPC
therapeutic potential and MS pathogenesis. Using our co-culture system, we
have characterized novel interactions between NPCs and specific CD4+ T-cell
subtypes. We have identified a previously undescribed mode of NPC
immunoregulation via FasL-dependent deletion of Th17 cells, and are the first to
report that Th1-cells in particular can directly harm NPCs. Cross-talk between
NPCs and TCs also modulates the production of FasL in either cell type: coculture leads to increased FasL in NPCs, but decreased FasL in Th17 cells. This
study sheds light on neuroimmune communication by identifying novel
mechanisms mediating cross-talk between NPCs and T-cells.
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Figure 4-1: Four color flow cytometry analysis
A. The Y-axis shows DSRed positive cells (autofluorescent NPCs). The X-axis
shows Cy5.5 positive cells (T-cell receptor stained). NPC gates and T-cell gates
were created from the two populations. B. Representative sample analysis of
dead (UV+) and apoptotic (Annexin-647+) cells from gated populations in (A).
Shown are control samples (top panels) and co-culture samples (bottom panels)
from a representative Th17 co-culture experiment. Subsequent graphs within this
article show percentage of live/healthy cells (lower left quadrant, negative for
either dye).
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Figure 4-2: Confirmation of the Th1, Th2, and Th17 subtypes following
polarization
Supernates from T-cell cultures were collected at the end of the polarization/restimulation process and ELISA for characteristic cytokines was performed.
Shown are average cytokine levels for each subtype: (A) Th1, (B) Th2, and (C)
Th17. n=5 representative experiments.
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Figure 4-3: Th2 and Th17 T-cells do not induce NPC death
Results from 48hr co-culture experiments. Activated and polarized T-cells were
added in excess to NPCs growing in a monolayer (80% confluency) in modified
RPMI media. After the co-culture period, flow cytometry UV/Annexin staining (for
dead and apoptotic cells, respectively) was performed on Th2 cultures (A) or
Th17 cultures (B). Shown are the percentage of live/healthy NPCs (negative for
UV and Annexin dyes, see Figure 1). n=6. LPR= Fas receptor deficient NPCs.
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Figure 4-4: Th1 induced NPC death is dose- and contact-dependent
(A) Results from Th1 co-cultures performed as described in Figure 1. NPC
viability decreases as ratio of T-cells increases. n= 4 (B) Th1 co-cultures
performed with transwell inserts (0.4um pores; prevents cell-contact while
allowing media exchange) or lpr NPCs. Lpr NPCs lack Fas receptor expression,
therefore the observed Th1-induced death is Fas-independent. n=3, *p<0.05,
**p<0.01
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Figure 4-5: NPCs induce pro-inflammatory Th1 and Th17 cell-death, but not
Th2
(A-C) T-cell viability data from co-cultures as described in Figure 1. Co-cultures
were perfomed using wild-type (WT) or lpr NPCs simultaneously so that the role
of Fas in observed effects could be determined. (A) dose-dependent Th1 cell
death. n=4 (B) Striking induction of Th17 cell death. n=7 (C) absence of death
induction in Th2 co-cultures. n=6, *p<0.05; **p<0.01. TC=T-cell.
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Figure 4-6: NPC-induced Th17 apoptosis is via cell-contact dependent
Fas/FasL interactions
Th17 co-cultures were performed with wild-type NPCs in either cell contact or
transwell conditions. In other co-cultures, gld NPCs, which do not express FasL,
were used in lieu of wild-type NPCs. n=4, p<0.01
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Figure 4-7: Co-culture effects on FasL Expression in different cell types
All relative gene expression values were calculated using 2-ΔΔCt method, β-actin
as the endogenous control gene, and choosing the appropriate calibrating
samples. For calibrating samples, (Th17 cells in (A); NPC control in (B), and Tcell control in (C)) relative expression is set to equal 1, and all other values are
expressed as a fold change relative to that. (A) FasL expression was determined
in T-cell control samples (RPMI media alone). Shown is fold increase of FasL in
Th1 and Th2 cells compared to Th17 cells (control/complete RPMI samples) (B)
Relative FasL mRNA levels in NPCs in co-culture compared to NPC alone
controls. (C) Relative FasL mRNA levels in Th1 and Th17 cells at two different
NPC:TC ratios compared to T-cell alone controls. *p<0.05, **p<0.01; n=4.
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Figure 4-8: Summary- Mechanism for NPC immunomodulatory functions
The capacity of NPCs to regulate inflammatory niches is primarily through direct
induction of encephalogenic Th1 and Th17 T-cell death.
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CHAPTER 5: SUMMARY & CONCLUSIONS

MS is a chronic, debilitating disease characterized by CNS inflammatory lesions
and a variable clinical course. Autoreactive immune cells drive demyelination and
resulting axonal degradation. This forms the cellular and molecular basis for the
majority of symptoms MS patients experience. MS generally begins as a
relapsing-remitting disease, but later becomes progressive without remission.
Repeated bouts of inflammatory episodes are thought to contribute to disease
pathology by damaging the endogenous NPC compartment and thus interfering
with NPC-mediated repair. Therefore, the introduction of new, undamaged cells
via NPC transplantation is a novel and promising avenue for treating MS
because exogenously administered NPCs may be able to circumvent damaged
CNS NPC niches and promote neuroregeneration.

Although NPC transplantation produces significant clinical improvement the main
animal model of MS (EAE), there are several pitfalls with this therapy that need
to be addressed before clinical translation in a human population possible.
Specifically, low post-transplantation survival of injected cells and ineffective
differentiation/integration into CNS tissue are two key issues. As opposed to cellreplacement, originally hypothesized to be the main mechanism NPCs would
improve clinical symptoms, NPCs alter disease course via bystander functions
such as secretion of neuroprotective factors and down-modulation of immunemediated inflammation. Despite the significant data indicating that NPCs are
154

effective at treating EAE via bystander mechanisms, detailed knowledge
regarding the key modulators of NPC survival, differentiation, and immune-cell
interactions is lacking. Addressing these gaps is critical to advancing NPC
therapeutic strategies as well as understanding MS disease progression.

The goal of my dissertation research was to characterize the roles of Fas in NPC
survival, differentiation, and T-cell cross-talk. Fas, a member of the tumor
necrosis superfamily of death receptors, has well-characterized functions in the
immune system and in developmental programmed cell death in the CNS. In
addition to apoptosis-mediating functions, Fas has diverse roles in various cell
types from T-cells to neurons to endothelial cells. Despite reports that NPCs
express Fas, its functions in this specific cell type were previously unelucidated.
Overall, this dissertation reveals Fas functions in NPCs in vitro (Specific Aim 1),
advances this understanding to how these mechanisms are important in NPC/Tcell cross-talk (Specific Aim 2), and finally tests this paradigm in vivo (Specific
Aim 3).

The Fas system plays a multifaceted role in NPC biology
Using recombinant Fas ligand (FasL) I found that activation of Fas receptor (Fas)
increases NPC survival in normally death-inducing conditions (growth-factor
deprived medium). The increase in NPC survival results from Fas-mediated
inhibition of apoptosis as opposed to a promotion of proliferation. This is in stark
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contrast to T-cells, wherein activation of Fas via FasL results in formation of the
death-inducing signaling complex (DISC) which activates caspase-3 to induce
apoptosis. Since flice-like inhibitory protein (FLIP) upregulation in other cell types
has been associated with resistance to Fas-mediated cell death, I examined FLIP
levels in treated or control NPCs. Unlike T-cells, cleaved/DISC associated FLIP
was not detected in NPCs. This, along with caspase-3 and -8 levels remaining
constant, suggests that Fas in NPCs does not signal through DISC. Therefore,
some other signaling molecules must mediate the anti-apoptotic effects of FasL.

In order to determine which pathways may mediate these effects, I ran a
screening “Apoptosis” RT2 ProfilerTM PCR array comprehensive of apoptosisassociated genes from several distinct signaling pathways. Of the over 80 genes
tested, Birc3 - a member of the inhibitor of apoptosis (IAP) family of proteins was the only anti-apoptotic gene with significant fold-upregulation upon FasL
treatment. My study was the first to correlate Birc3 levels with Fas activation in
any cell type, and the first to implicate Birc3 in NPC pro-survival. To ensure the
anti-apoptotic effects are mediated via Fas and not another non-specifc pathway,
I treated Fas receptor-deficient (lpr) NPCs with FasL. Birc3 levels remained
unchanged in lpr NPCs treated with FasL, confirming FasL is working specifically
through Fas in wild-type NPCs.
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In order to further characterize the role of Fas in NPC survival, differentiation,
and proliferation I utilized our lpr (Fas-Deficient) line of NPCs. In comparison to
wild-type NPCs, lpr NPCs exhibit enhanced differentiation to neuronal and oligolineages. I confirmed the altered differentiation capacity of lpr NPCs using RTqPCR, flow cytometry surface staining (A2B5, putative OPC marker), and
immunocytochemistry (βIII-tubulin and PDGFRα). The exact mechanisms
responsible for this difference in multipotentiality remains to be elucidated. The
“Neurogeneis and Neural Stem Cell” focused RT2 ProfilerTM PCR array identified
Shh, Noggin, and Hes1 as potential modulators of the enhanced neuronal and
OPC fate-specification seen in lpr NPCs. Levels of these particular gene
transcripts are significantly upregulated in lpr NPCs compared to wild-type after 7
days in differentiating media. Lpr NPCs also have abrogated proliferative
capacity compared to wild type NPCs demonstrated by both decreased BrDU
incorporation and smaller sphere size over several passages. Lastly, I found that
lpr NPCs have enhanced survival compared to wild type NPCs in growth factordeprived conditions. This improved survival in a stress-inducing environment,
may actually contribute to the enhanced differentiation abilities of lpr NPCs. It is
possible that an increased percentage of cells surviving in the absence of growth
factors allows for a higher number of cells to activate differentiation pathways.
Overall, my data suggest that Fas plays an important, multifaceted role in
NPC survival, differentiation, and proliferation (Figure 5-1).
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Figure 5-1: Roles of Fas in neural progenitor cells
The exact role of Fas in NPC survival, proliferation, and differentiation is
dependent on both environmental cues (FasL) and cell expression of Fas.
Activation of Fas via FasL results in decreased apoptosis by upregulation of the
anti-apoptotic protein Birc3. Absence of Fas results in upregulation of
compensatory signaling pathways that result in decreased apoptosis, decreased
proliferation, and increased differentiation to neuronal and OPC phenotypes.
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The presence of a functional Fas receptor on NPCs as well as the availability of
activating signals (FasL) contribute to determining effect of the Fas system on
NPC fate. From my first experiments, I found activation of Fas using recombinant
FasL results in increased survival of NPCs in a growth factor-deficient
environment and that FasL treatment does not effect either NPC proliferation or
differentiation capacity. Based on this data I originally hypothesized that, since
FasL acts as a survival signal for NPCs, the absence of Fas should result in
increased NPC death without affecting differentiation or proliferative capacity.
However, I found that lpr (Fas-deficient) NPCs exhibit increased survival,
increased differentiation to neuronal and oligoprotenitor phenotypes, and
decreased proliferation compared to wild-type NPCs.

There are two possible explanations for these results. First, it is probable that
functional Fas in the absence of FasL is not “silent,” but actually inhibits the
differentiation of NPCs (Figure 5-2a). Other factors in the media may nonspecifically activate Fas and promote alternate, inhibitory signaling cascades in
NPCs. Thus, lpr NPCs exhibit increased differentiation, in comparison to wildtype NPCs, because they lack this inhibitory signal. Furthermore, in the absence
of FasL signaling cells to survive, pro-apoptotic “default” pathways may
predominate within Fas-expressing wild-type NPCs.
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Figure 5-2: Predominating signals in wild-type NPCs
Unactivated Fas (scenario a.) inhibits differentiation to OPC and neuronal
phenotypes while allowing default apoptotic pathways to predominate. These
outcomes are likely mediated via Fas interacting with currently unknown adaptor
molecules and/or various signaling pathways (red arrows). This serves as a
possible explanation as to why Fas-deficient (lpr) NPCs exhibit both increased
differentiation and decreased apoptosis (they lack both signals). However,
activation of Fas via FasL (scenario b.) results in predominating signaling
cascades (involving Birc3) which ultimately result in increased NPC survival (by
inhibiting apoptosis).
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In other words, if NPCs are exposed to FasL, survival will be increased (Figure 52b); however, if NPCs reside in a FasL-deficient environment, a functional Fas
system is detrimental to survival (Figure 5-2a). This would explain why lpr NPCs
have increased survival in comparison to wild-type, as FasL levels are essentially
undetectable in serum-free cultures (Knight, 2009).

Secondly, it is also possible that the altered phenotype seen in lpr NPCs is due to
abnormal embryological development resulting from an absence of Fas. Lack of
Fas in developing NPCs may induce compensatory pathways that dictate the
altered phenotype exhibited by lpr NPCs. In order to determine if differences
observed in the lpr NPC cell line are due to developmental abnormalities or the
absence of Fas itself, one would have to re-introduce Fas to lpr NPCs and see if
this reverts the mutant NPC line back to the wild-type phenotype. If reintroduction of Fas to lpr NPCs does not alter their characteristics as expected,
then developmental alterations are responsible the reported results. If this is the
case, it would be of interest to explore what developed compensatory pathways
drive the increased survival and differentiation profiles in lpr NPCs because these
signaling pathways/molecules represent novel targets for controlling NPC fate.
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NPCs can specifically target and kill pro-inflammatory T-cells and FasL is a
critical mediator of this process
Since Fas plays a complex, multifaceted role in NPC fate-determination and it
also has well-characterized functions regulating homeostasis in the immune
system (by deleting autoreactive T-cells via FasL mediated apoptosis), I
hypothesized that Fas is an important mediator of NPC/immune cell cross-talk. In
order to test this hypothesis, I developed a co-culture system where I could
determine outcomes of both NPCs and T-cells. Because CD4+ T-cells are
considered the main mediators of disease pathogenesis MS, I focused on three
CD4+ T-cell subsets in my study (Th1, Th17, and Th2). For each experiment I
used lpr NPC co-cultures (in addition to wild-type) in order to determine the role
of Fas expression in any observed interaction. My research is novel in two
respects; first, no former literature details the effect specific T-cell subtypes have
on NPCs. Secondly, I am the first to examine the interaction between NPCs and
pro-encephalogenic Th17 cells.

Effects of T-cells on NPCs
Of the CD4+ T-cells tested, only Th1 cells are able to directly induce NPC cell
death. This apoptosis occurs in a contact-dependent and Fas-independent
manner. It is of interest to elucidate which surface molecule on Th1 cells has the
ability to kill NPCs because antagonizing this process represents a novel
therapeutic target. Th1-mediated NPC death may contribute to infiltrating
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immune cells impeding the endogenous stem cell compartment and promoting
neurodegenerative processes

Effects of NPCs on T-cells
The ability of NPCs to inhibit pro-inflammatory Th17 cells is two-fold. First, NPCs
induce significant Th17 cell death. These effects are mediated via cell contact
and are not altered by lack of Fas expression in NPCs (i.g. lpr and wild-type
NPCs produced similar results). In contrast to expression of the receptor, I found
that expression of the cognant ligand (FasL) on NPCs is needed in order for
NPC-mediated Th17 apoptosis to occur. This was demonstrated by abrogation of
Th17 cell death when co-cultures where performed with FasL-deficient (gld)
NPCs. Secondly, co-culture with NPCs decreases the expression of FasL on
Th17 cells. Since FasL has been shown to be toxic to neurons and
oligodendrocytes, preventing the overproduction of FasL within the CNS is most
likely beneficial (Giuliani et al., 2003; W. Li et al., 2002). Therefore, NPC
modulation of Th17 FasL production may be another important mechanism for
immunoregulation in favor of neuroprotection.

Futhermore, my study supports prior data that NPCs can specifically kill proinflammatory Th1 T-cells, but not anti-inflammatory Th2 cells (Pluchino et al.,
2005). Overall, my data indicate that the major mechanism for NPC
immunoregulation is inhibition of pro-inflammatory T-cells (Figure 5-3). However,
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unlike NPC FasL expression, which is critical to NPC-induced encephalogenic Tcell death, NPC expression of Fas receptor does not influence their
immunomodulatory capacity since lpr and wild-type NPCs induced proinflammatory T-cell death to the same extent.
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Figure 5-3: Mechanism for NPC immunomodulatory functions
The capacity of NPCs to regulate inflammatory niches is primarily through direct
induction of encephalogenic Th1 and Th17 T-cell death. *From Knight, et al.,
accepted to Journal of the Neurological Sciences (Chapter 4).
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NPC Fas receptor expression does not impact transplantation efficacy

Based on results detailed in Chapter 3, I hypothesized that the enhanced
differentiation and survival capacities of lpr NPCs may contribute to better posttransplantation survival and CNS integration, consequently leading to improved
clinical outcomes in EAE. To test this hypothesis, we injected either wild-type or
lpr NPCs into mice during the height of EAE inflammation (14 days postimmunization). Clinical scores for NPC or vehicle (PBS) control injected mice
were recorded over acute and chronic time points. Mice brains and spinal cords
were analyzed for inflammatory infiltrate via immunohistochemical analysis for
CD45+ cells. GFP+ NPCs were visualized in periventricular and parencymal areas
of the brain as well as in the spinal cord.

Though the number of NPCs entering the CNS was scarce, the NPCs exhibited a
strong capacity for localizing to inflammatory sites (Appendix A, Figure A-2). Both
lpr and wild-type NPCs decreased EAE clinical scores to the same extent at the
acute timepoint (Appendix A, Figure A-3 & A-4). Furthermore, amount of CNS
infiltrating immune cells was decreased equally in both lpr and wild-type NPC
injected groups compared to controls (Figure A-5). For the chronic timepoint,
average clinical scores in NPC treated groups were not significantly different
compared to PBS control mice (Figure A-3). However, the cumulative disease
score was much lower in both lpr and wild-type treated groups compared to PBS
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controls (Table A-1). All relevant EAE data is summarized in Table A-1. Taken
together, these results lead me to reject my original hypothesis.

Even though lpr NPCs have significantly higher differentiation and decreased
apoptosis compared to wild-type NPCs in vitro, this did not translate to promoting
terminal differentiation and post-transplantation survival in vivo. It is possible that
there are environmental factors unique to the CNS compartment which prevents
the differentiation of transplanted NPCs, regardless of their inherent
differentiation capacities. Conceivably, inflammation itself may contribute to the
inhibition of differentiation. This hypothesis is supported by numerous prior
reports of injected NPCs remaining in a “progenitor,” undifferentiated state
(Einstein et al., 2006; Einstein et al., 2003; Pluchino et al., 2005). Identifying what
molecules are responsible for inhibiting NPC differentiation in vivo warrants
further investigation because modulating these signals could promote
oligodendrocyte production and remyelination, ultimately resulting in more
effective CNS repair.

Since inflammation itself may prevent terminal differentiation and integration of
transplanted NPCs, it would be of interest to test the ability of lpr NPCs to
effectively differentiate to oligodendroctyes in an in vivo model that lacks chronic
CNS inflammation. The cuprizone model of toxic demyelination would be a viable
alternative. Because, in contrast to EAE, the cuprizone model lacks inflammatory
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confounding factors and this model is characterized by extensive demyelination
(Torkildsen, 2008). However, a downside of cuprizone-induced demyelination is
the lack of clinical manifestations (Torkildsen, 2008). Furthermore, since we are
interested in developing NPCs as a therapy for MS, a complex disease wherein
inflammation and neurodegeneration are intimately associated, EAE remains the
most relevant animal model.

I originally hypothesized that the increased survival exhibited by lpr NPCs would
result in more abundant NPC/immune cell interactions, thus improving their
immunoregulatory capacity and ability to improve EAE disease course. As
explained above, this hypothesis was not supported by my data. In lieu of my
former hypothesis, I would propose the following explanation. Since only a very
small number of NPCs actually enter the CNS and are required for clinical
improvement, survival differences between lpr and wild-type NPCs become
insignificant. Furthermore, since my co-culture data reveal that the
immunomodulatory capacity of NPCs is not affected by their Fas-expression and
considering peripheral/ “bystander” immunoregulatory functions of NPCs are
most likely primarily responsible for improving disease outcomes (Ben-Hur, 2008;
Pluchino & Martino, 2008) – it is not surprising that lpr and wild-type NPCs have
the same efficacy in EAE.

168

Concluding Remarks
Although Fas plays multifaceted roles in NPC fate specification in vitro,
modulation of the Fas receptor proved not to be an effective method for
improving transplantation efficacy. Despite this, NPC transplantation therapy
remains a viable approach in development for MS. In particular, the ability of
NPCs to home to areas of inflammation within the CNS may provide substantial
benefit compared to currently utilized peripheral immunotherapies. Little evidence
exists for any currently used MS drug crossing the blood brain barrier. If NPCs
are able to localize to CNS lesions and exert regenerative and
immunomodulatory effects directly at the site damage, then NPCs may be able to
more effectively prevent the chronic neurodegeneration that occurs in MS despite
aggressive pharmacotherapy.

My data shows NPCs can specifically regulate Th17 T-cells via direct apoptosis
as well as inhibiting FasL production. These findings are important and give
further credence for the potential of NPCs as a novel therapy for MS because
Th17 cells are regarded as the major, extremely pro-encephalogenic mediators
of CNS damage. Since immune interactions driving MS pathology are extremely
complex and are required for many reparative processes to take place, it is
important to find a therapy that can specifically target pro-inflammatory cells
without altering anti-inflammatory, reparative processes. NPCs seem ideal for
this since they specifically kill Th1 and Th17 cells without affecting Th2 survival.
Because of NPC’s robust immunomodulatory capacity, they may provide
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significant benefit during both the relapsing-remitting and the neurodegenerative
phases of MS considering immunological compromise is present over the entire
clinical course (Frischer et al., 2009).

Some major questions remain for the viability of NPC transplantation therapies.
1) What factors can be altered either in vivo or in vitro to enhance NPC
differentiation and terminal integration? 2) If NPC differentiation can be improved,
would this positively affect clinical outcomes? Both questions warrant future
investigation. It is entirely possible that the only viable mechanism for NPCs to
improve MS is via bystander immunoregulation. Further investigation into
NPC/immune cell cross-talk will reveal other factors important in this
communication and holds the possibility for determining novel therapeutic
targets. If we can better understand, and change, how invading T-cells influence
the endogenous NPC compartment we may be able to supersede the need to
transplant stem cells by preventing NPC niche damage and promoting
neuroregeneration pharmacologically.
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APPENDIX A: Efficacy of wild-type and lpr NPC transplantation in EAE

Introduction
Based on results from in vitro experiments comparing wild-type (wt) and lpr
NPCs (Chapter 3), I hypothesized that lpr NPCs would have enhanced efficacy
when transplanted into mice with EAE. The enhanced differentiation of lpr NPCs
into neuronal and oligo-progenitor lineages could result in increased terminal
differentiation and integration of transplanted cells within the host CNS.
Furthermore, the increased survival of lpr NPCs compared to wt NPCs in the
absence of growth factors could result in enhanced immunoregulatory capacity of
lpr NPCs in vivo. If a higher number of NPCs survive the transplantation process,
perhaps this would lead to increased interactions between NPCs and immune
cells allowing NPCs to decrease inflammation more efficiently. One or both of
these mechanisms could contribute to enhanced clinical recovery in mice treated
with lpr NPCs compared to wt.

Methods
NPC Isolation
Brains were dissected from 4-day post-natal wt or lpr mouse pups (C57BL/6).
NPC were extracted using NeuroCult® Enzymatic Dissociation Kit (Stem Cell
Technologies) and plated in EGF and FGF containing medium. Neurospheres
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were formed after 8-12 days in culture and the expression of Nestin (a putative
stem cell marker) was confirmed using confocal microscopy.

NPC Culture & Preparation
Our wt and lpr NPC lines were transduced (lentivirus) with green fluorescent
protein (GFP; courtesy Dr. Jeffery Spees, Director of the UVM Stem Cell Core).
GFP+ Transfected NPCs expanded and were sorted to >85% purity using BD
FACS Aria high-speed cell sorter (UVM COM Flow Cytometry Center).

Sorted, GFP+ NPCs were plated in a monolayer on Poly-D lysine and laminin
coated T-75 flasks (Nunc) in mouse-NPC complete media consisting of Gibco®
Neural basal media, B-27 supplement, penicillin/streptomycin (10 mg/mL), Lglutamine (29.20 mg/mL) EGF (10 ng/mL) and FGF (10 ng/mL). NPCs were
allowed to grow to confluency for 3-5 days. At time of injection, NPCs were lifted
from flasks using 0.05% trypsin (7 min at 37°C). Trypsin reaction was stopped
using 20% FCS/Neural basal media. Cells were counted, rinsed, and
resuspended in sterile phosphate buffered saline (PBS) at a concentration of
1x106 cells/50 µL.

Retro-orbital NPC Injections
Mice were anesthetized using isoflourane (Webster Veterinary) before injected
50 µL of the cell solution (1x106 cells ) into the retro-orbital sinus using a 27 ½

188

gage syringe and then mice were observed until full motility returned. Mice
receiving the vehicle control of sterile PBS were injected with the same volume of
solution (50 µL) as the mice injected with cell solution. Cells were injected into
mice immediately after suspension in sterile PBS and syringes were kept on ice
in order to minimize the amount of cell death during the injection procedure.

EAE Induction and Clinical Time Points
Mice were first immunologically primed with a subcutaneous injection of 200 µg
MOG (myelin oligodendrocyte glycoprotein)/CFA (complete Freud’s adjuvant). A
second 200 µg MOG/CFA injection was given seven days later (considered “Day
1” of the protocol). On Day 1, mice were also given a 200 ng PTX (pertussis
toxin) intraperitoneal (IP) injection followed by a second 200 ng PTX injection 2
days later. Mice were sacrificed at Day 21 (acute time point) or at Day 34
(chronic time point). The induction and clinical protocol is summarized in Figure
A-1.

EAE Clinical Scoring
Clinical scoring of EAE symptoms began on day 7 of the induction protocol and
continued daily including the day of sacrifice. Mice generally started presenting
with symptoms on days 9-11. The scoring criterion used in this study is a wellestablished 5 point scoring scale where: 0 = no clinical symptoms, 1 = limpness
in tail, 2 = hind limb ataxia, 3 = hind limb paralysis, 4 = hind limb paralysis with
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incontinence and 5 = quadriplegia or paraplegia with clear forelimb weakness
and moribund state. Scoring was conducted by a trained participant blinded to
the treatment groups.

Tissue Sample Harvesting
Mice were given a 50 µL lethal dose of Nembutal® (Ovation) intraperitoneally.
Intracardial perfusion was then performed using PBS followed by 10% formalin.
Brains and spinal cords were then dissected and placed in 15 mL of 10%
formalin and left to fix at room temperature for 24 hours. To remove fixative,
samples were rinsed three times with PBS. Afterwards, samples were
cryoprotected with sucrose gradients (tissue submerged in a 15% sucrose
solution/0.2% azide in PBS on a rocker at 4C for 24 hours followed by a 30%
sucrose solution on a rocker 4C for 24 hours). Samples were then frozen in
NEG 50™ (Richard Allen Scientific) and stored in sealed plastic tubes at -80C
until they were sliced. Samples were sliced using a cryostat at 20 µm section
thickness and sections were stored and stained on microscope slides
(Fisherbrand Superfrost Plus).
Immunohistochemistry
All sample slides were baked at 37°C for 15 min before the staining process
began. Sample slides were stained for inflammation, after blocking in 10% goat
serum/0.4% triton in PBS for 1 hour at room temperature, with an αCD-45 1°
antibody (rat, Millipore 1:750) at 4°C for 24 hours. Slides were then rinsed with
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PBS and a αRT-CY3 2° antibody (Jackson 1:500) was applied for 1 hour at room
temperature. Before mounting, slides were stained with Hoecsht (1:2000).
Samples stained for stem cell differentation markers were baked and blocked in
the same fashion as those stained for inflammation. The primary antibodies used
to stain for these markers included platelet-derived growth factor receptor-alpha
(PDGFRα, rabbit, Santa Cruz 1:50 in 10%HS in PBS), beta III-tubulin (rabbit,
Sigma 1:100 in 10% goat serum/0.4% triton in PBS) and glial fibrillary acidic
protein (GFAP, rabbit, dako 1:250 in 10% goat serum/0.4% triton in PBS). After
the primary was rinsed off with PBS after the 24 hour incubation at 4°C, αRb-CY3
2 antibody (Jackson 1:500) was applied for 1 hour at room temperature and
slides were stained with Hoecsht (1:2000) before mounting.
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Figure A-1: EAE induction, treatment, and analysis timeline
Experimental protocol summary illustrating induction procedures, treatment timepoint and clinico-pathological chronology. Mice were retro-orbitally injected with
NPCs or PBS vehicle control at day 14, 1 week after 2nd MOG injection. At time
of treatment (day 14), mice had exhibited clinical symptoms for 3-5 days. Mice
were sacrificed either 7 days later (acute timepoint), or 20 days later (chronic
timepoint) and brains were harvested for immunohistochemical analysis. Clincal
scores for each mouse were recoreded over the entire experiment, starting at
day 7).

192

Results

Figure A-2:Retro-orbitally injected NPCs migrate to and reside with the CNS
Representative image (combination of multiple 20x images) of periventricular
brain section with GFP+ NPCs (green cells) in close association with infiltrating
immune cells (red, CD45+).
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Figure A-3: NPC treated mice show greater decrease in clinical scores
post-injection than PBS treated mice
(a) Mean clinical scores from each day after injection.
(b) Mean clinical scores at the day of harvesting at the acute time point for lpr
(n=11, p≤0.05), wt (n=10, p≤0.01) and PBS (n=9) treated mice.
(c) Mean clinical scores at the day of harvesting at the chronic time point for
lpr (n=5), wt (n=5) and PBS (n=5) treated mice.
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Figure A-4: Recovery at the acute time point is greater in NPC treated mice
than in PBS controls
(a) Mean improvement in clinical score for lpr (n=11, p≤0.05) wt (n=10, p≤0.01)
and PBS treated mice at the acute time point. Improvement in clinical score was
determined by subtracting the clinical score at sacrifice from the clinical score at
NPC injection. (b) Percent of mice showing recovery at acute time point for lpr
(n=11, p≤0.05), wt (n=10) and PBS (n=9). A mouse was considered to be
showing recovery if the clinical score at the time of sacrifice was less than the
clinical score at the time of NPC injection.
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Figure A-5: Periventricular brains and lumbar spines of mice treated with
NPCs show a significant decrease in the amount of inflammation at the
acute time point when compared to mice treated with PBS
(a) Mean average object density of CD-45 positive cells in lpr (n=6, p≤0.05), wt
(n=4, p≤0.05) and PBS determined using Neurolucida image processing
software. (b) Representative 20x images of lumbar spinal sections of lpr (left), wt
(middle) and PBS (right) stained for CD-45 (red cells).
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A-1: Clinco-pathologicalSummary
summary of of
EAE
studyStudy





*

*

**

*

 Data are mean numbers (SEM) from a total of n=3 independent experiments.
The mean disease score represents the scores of all mice in each group at the endpoint of each clinical period.
The cumulative disease score is the summation of all scores over the entire clinical period (20 days) in each group.
Inflammatory infiltrates are characterized by the mean optical density of CD45 positive cells in periventricular brain and lumbar spinal cord sections.
*p0.05 when compared to PBS injected controls.
**p0.01 when compared to PBS injected controls.

Discussion
To test weither lpr NPCs have superior clinical efficacy, we transplanted GFPlabeled NPCs (either wt or lpr) into mice afflicted with EAE. Contrary to our
original hypothesis, both lpr and wt NPCs resulted in similar reductions in clinical
scores (Figure A-2 & A-3) and CNS inflammation (Figure A-4). These results
could be the result of in vivo envitronmental factors that inhibit the differentiation
of NPCs, despite their inherent capacity. Furthermore, if the primary mechanism
for NPC-mediatied clinical benefit is via immunomodualtion, one would not
expect to see differences between lpr and wt NPC efficacy since they posses the
same abilities to immunoregulate (Chapter 4). Further studies are needed to
determine: (1) factors that impede NPC differentiation in vivo and (2) whether
methods to enhance NPC-mediated immunomodulation would positively affect
clinical outcomes.
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